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1. INTRODUCTION 
                                                                        (Mathiowitz E., 2009)       
Since the  early  1980s  there  has  been  renewed  interest  in  the  use  of 
bio adhesive  polymers to prolong contact time in the various mucosal routes of 
drug administration. 
The ability to maintain a delivery system at a particular location for an 
extended period of time has great appeal for both local as well as systemic drug 
bioavailability. 
Drug absorption through a mucosal surface is efficient because mucosal 
surfaces are usually rich in blood supply, providing rapid drug transport to the 
systemic circulation and avoiding degradation by gastrointestinal enzymes and first 
pass hepatic metabolism. 
 
1.1 Oral Trans mucosal Drug Delivery: 
                                          (Donald L.W., 2005; Chien Y. W., 2009; Robinson J.R., 2005)                       
Within the oral cavity delivery of drug is classified into the categories. 
Absorption of drug via mucous membranes of the oral cavity was noted as early as 
1847 by Sobvero, the discoverer of nitroglycerin, and systemic studies of oral 
cavity absorption was first reported by Walton in 1935 and 1944. 
Due to its excellent accessibility and reasonable patient compliance oral 
mucosal cavity offers attractive route of drug administration. Within the oral 
mucosal cavity delivery of drug is classified into three categories (I) Sublingual 
delivery which is a systemic delivery of drug through the mucosal membrane 
lining the  floor  of  the  mouth  (ii) Buccal  delivery  &  local  delivery,  for  the 
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treatment of conditions of the oral cavity. 
The oral cavity is foremost part of digestive system of human body.  It is 
also referred to as “buccal cavity”.  It is accountable for various primary functions of 
body.  The careful examination of various features of oral cavity can help in 
development of a suitable buccoadhesive drug delivery system. 
 
1.2 ORAL CAVITY:                                                            
(Mathiowitz E., 2009; Rathbone M.J.et al., 1996; Vyas S.et al., 2002) 
 
1.2.1Components or structural features of oral cavity:  
Oral cavity is that area of mouth delineated by the lips, cheeks, hard palate, soft 
palate and floor of mouth. The oral cavity consists of two regions. 
• Outer oral vestibule, which is bounded by cheeks, lips, teeth and gingiva 
(Gums). 
• Oral cavity proper, which extends from teeth and gums back to the 
fauces (Which lead to pharynx) with the roof comprising the hard and 
soft palate. The tongue projects from the floor of the cavity. 
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Figure-1.1: Structure of Oral Cavity 
 
 
 
1.2.2 Anatomical Features: 
 
The outer surface of the oral cavity is a mucous membrane consisting of an 
epithelium, basement membrane and lamina propria overlying a submucousa 
containing blood vessels and nerves.  The mucosa can be divided into three types: 
• Masticatory mucosa, found on the gingiva and hard palate. 
• Lining mucosa, found on the lips, cheeks, floor of mouth, undersurface 
of the tongue and the soft palate. 
• Specialized mucosa found on the upper surface of the tongue and parts 
of the lips. 
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All consists of a squamous stratified epithelium, many cell layers (40-50 
for buccal mucosa) overlying a connective tissue, layer, the lamina propria. 
 
 
 
 
 
 
 
 
Epithelium 
 
 
 
 
 
 
 
 
 
 
 
 
Lamina 
Propria 
 
 
 
 
 
 
 
Submucosa 
 
 
 
 
Figure-1.2: Structure of Buccal Mucosa 
 
 
 
The total surface area of oral cavity= 170 cm². 
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Table-1.1: Thickness and surface area of oral cavity membranes 
 
Oral cavity membrane Thickness (mm) Surface area (cm²) 
Buccal mucosa 500-600 5.2 
Sublingual mucosa 100-200 26.5 
Gingival mucosa 200 -- 
Palatal 250 20.1 
 
 
 
 Intercellular connection in buccal tissue are characterized by desmosomes 
and  tight   junctions  and  the  tissue  is  a  somewhat  leaky  epithelium.The 
intercellular material between the superficial epithelial layers is extended by a 
unique organelle called “membrane coating granule”.   It has been shown In rat 
keratinized  epithelium,  that  the   lamella  contents  of  the  membrane-coating 
granules mix with existing material and form  broad sheets in the intercellular 
spaces.  These sheets are oriented parallel to the cell membrane and therefore 
may act as a barrier to permeability.  Connective tissue papillae, which penetrate 
into  the  epithelia,  give  the  basement  membrane  an  enormous  surface  area 
compared to that of the surface of the epithelium. 
 
1.2.3 Biochemistry of oral mucosa:  (Rathbone M.J.et al., 1996.)                   
 
 All the layers of the oral mucosal membranes contain a large amount of 
protein in the form of ton filaments, consisting at least seven proteins called 
“keratins” with molecular sizes of 40-70 Kda.  Keratinized and non- keratinized 
tissues of varying thickness and composition are found in oral cavity. Keratinized and 
non-keratinized tissue occupies about 50% and 30% respectively of the total surface 
area of the mouth.   The difference between keratinized and non-keratinized 
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epithelia is merely the difference in the molecular size of existing keratins. Cells  of  
non-keratinized  epithelia  contain  lower  molecular  weight protein  while  those  in  
keratinized  epithelia  contain  mainly  higher-molecular- weight keratins.  The lipid 
content of the cells varies between tissues. 
 
 
 
Table-1.2: Composition and state of keratinization of oral mucosa 
 
 
Tissue State of Keratinization 
 
Composition 
Buccal mucosa Non-keratinized Few neutral, but mainly polar 
lipids, particularly cholesterol 
sulfate and glucosylceramides Sublingual mucosa Non-keratinized 
Gingiva mucosa Keratinized Neutral lipids i.e., ceramides 
Palatal mucosa Keratinized 
 
 
1.2.4 Physiological aspects and functions of oral cavity: 
 
The oral cavity is accountable for the following primary functions: 
 
• As a portal for intake of food material and water. 
 
• To bring chewing, mastication and mixing of food stuff. 
 
• Lubrication of food material and formation of bolus. 
 
• Identification of ingested material by taste buds of tongue. 
 
• Initiation of  carbohydrate and fat metabolism.  Absorption of catabolic 
products thereafter  metabolism. 
• To aid in speech and breathing process. 
 
• Slight antisepsis of ingested material and within oral cavity by saliva. 
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1.2.5 Secretions of Oral Cavity                                         (Mathiowitz E., 2009) 
The secretions  in  the  oral  cavity  includes  saliva,  crevicular  fluid  and 
mucus. 
 
1.2.5.1 Saliva: 
 
 Saliva is a complex fluid containing organic and inorganic materials.  It is 
produced  by   the  three  pairs  of  major  glands  (parotid,  submandibular  and 
sublingual) each situated  outside the oral cavity and in minor salivary glands 
situated in the tissues lining most of the oral cavity.  The total average volume of 
saliva produced daily in an adult is around 750 ml. The flow rates of saliva 
depend upon the type of stimulus used, the time of day, the length of time glands 
had been stimulated, the age and sex of the individual and by their state of health. 
The average resting flow rate for whole saliva is 0.3 ml/ min (range 0.1-0.5 
ml/min).  For stimulated saliva the average flow rate is 1.7 ml/min (range 1.1 to 
3.0 ml/min).  Chemically, saliva is 99.5% water and 0.5% solutes.  The solutes 
include   ions   (sodium,   potassium,   magnesium,   phosphate,   bicarbonate   and 
chloride), dissolved gases, urea, uric acid, serum albumin, globulin, mucin and 
enzymes [lysozyme and amylase (ptyalin)]. 
 
The various physiological functions of saliva are: 
 
• Modulation of oral flora. 
• Remineralization of the teeth with calcium phosphate salts. 
• Neutralization of acid in the oral cavity and esophagus. 
• Lubrication  and  the  cleansing  of  the  oral,  pharyngeal  and  esophageal 
mucosae. 
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• Assistance in bolus formation. 
• Stimulation of epithelial proliferation. 
• Initiation of fat and starch digestion. 
 
The pH of whole saliva varies between 6.5 and 7.5.  The main buffering system is 
the bicarbonate system; however, phosphate and protein buffers also play a minor 
role. 
 
1.2.5.2 Crevicular Fluid: 
 
It is a fluid secreted from the gingival glands of oral cavity. 
 
 
 
1.2.5.3 Mucus: 
 
Mucus is a thick secretion composed mainly of water, electrolytes and a 
mixture  of  several  glycoproteins,  which  themselves  are  composed  of  large 
polysaccharides bound with smaller quantities of protein.  It is secreted over many 
biological membranes of body for example, throughout the gastrointestinal tract 
walls.  Mucus is secreted by special type of epithelia called mucosa.  The mucus 
secreted in buccal cavity admixtures with saliva of salivary glands in oral cavity to 
produce whole saliva. 
Mucus has two main functions: 
 
• Protectant for biological membranes (exposed epithelia). 
 
• Excellent lubricant. 
 
 
 
 The two main glycoprotein found in buccal mucus or mucin are MG1 and 
MG2. The mucin glycoprotein, MG1 consists of several disulphide-linked subunits 
containing a protein core with 4-16 oligosaccharide side-chain units.  Its molecular 
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size is over 1000 KDa. A small mucin glycoprotein, MG2 has a molecular 
weight of 200-250 KDa and consists of a single peptide chain with 2-7 
oligosaccharide side-chain units. 
 
The important characteristics of mucus are: 
 
• The glycoproteins of mucus have amphoteric properties and are 
therefore capable of buffering small amounts of either acids or alkalies. 
• Mucus is strongly resistant to digestion by proteases. 
 
• Mucus has adherent qualities that make it adhere tightly to the food or 
other particles and also to spread as a thin film over the surfaces. 
 
The mucin film on the surface of oral mucosa provides the 
pharmaceutical scientist  with  the  opportunity  to  retain  delivery  systems  
in  contact  with  the mucosa for prolonged periods using mucoadhesives.  
This mucus, however, acts as potential barrier to drug penetration. 
 
1.3 DRUG DELIVERY VIA ORAL CAVITY: 
The oral cavity can be used for local and systemic therapy.  
Examples of local therapy would be the treatment of oral infections, dental 
caries, mouth ulcers and stomatitis. The  buccal  route  is  of  particular  
interest  with  regard  to  the systemic delivery of small molecules that are 
subjected to first pass metabolism, or for the administration of proteins 
and peptides. The two main-routes for administration with oral cavity are: 
 
• Sublingual route 
 
• Buccal route. 
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1.3.1 Drug Delivery via Sublingual Route: 
 
Sublingual administration implies systemic administration of drugs via the 
membranes that line the floor of the mouth and ventral surface of the tongue.  A 
rapidly dissolving tablet   is   generally given by the sublingual route. The sublingual 
routes offer some distinct advantages. 
1. The  sublingual  mucosa  is  thinner  than  buccal  mucosa  and  hence  
has comparatively higher permeability to drugs. 
2. Rapid onset of action. 
 
3. Quick termination of drug effect by spitting tablets. 
 
 
Other advantages associated to this route are common to those of buccal 
absorption and discussed in later sections.  The sublingual regions suffer with one 
major drawback.  The two major salivary glands (submandibular and sublingual 
glands) open their ducts in sublingual area to release saliva.   There is constant 
flushing of saliva in this region because of which it is difficult to retain drugs and 
delivery  system  and  build  or  maintain  high  concentration  of   drug,  in  the 
sublingual region. 
 
 
 
1.3.2 Drug delivery via buccal route: 
 
Buccal delivery refers to drug release which can occur when a dosage 
form is placed in the outer vestibule between the buccal mucosa and gingiva. 
Various advantages and other aspects of this route are elucidated in latter sections. 
 
1.3.2.1 Terminology: 
 
Various terms to be used in theoretical elucidation of buccal absorption are 
discussed below: 
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• Oral cavity mucosa:  The membranes that line the oral cavity which 
include the sublingual, buccal mucosa, the gums (gingiva), the palatal 
mucosa and the labial mucosa. 
• Buccal membrane: The membrane inside the mouth that lines the cheek. 
• Buccal drug delivery system: A delivery system designed to deliver 
drugs systemically or locally via or to the buccal mucosa. 
• Salivary pellicle: The components of saliva are adsorbed on to the 
surface of the oral mucosa to form a salivary pellicle.  This pellicle 
coats all surfaces in the mouth and is a multilayered structure. 
 
1.4 BUCCAL ABSORPTION:                     (Bandyopadhyay A. K., 2008)                                                                                         
 
Buccal administration involves systemic or local administration via or to 
the buccal membrane. 
 
1.4.1 Mechanism: 
Oral mucosal drug absorption occurs by passive diffusion of the non- 
ionized species, a process governed primarily by a concentration gradient, through 
the intercellular spaces of the epithelium.   Beckett AH and his co-investigators 
showed using a variety of organic drugs from acids to bases, that the passive 
transfer of nonionic species across the lipid membrane of the buccal cavity was 
the primary transport mechanism.   The buccal mucosa has been said to behave 
predominately as a lipoidal barrier to the passage of drugs; as is the case with 
many other mucosa and (within limits) the more lipophilic (or less ionized) the 
drug molecule, the more readily it is absorbed.   It has been concluded that the 
passive diffuses in accordance with the pH partition theory of drug absorption is 
the major route of drug absorption for most drugs.  However, it has been reported 
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that certain molecules e.g., some sugars and vitamins may be transported by a 
specialized transport system capable of saturation. 
 
It  has  been  proposed  that  the  intercellular  route,  rather  than  the 
transcellular   route,  is  the  predominant  route  for  drug  absorption. Large 
hydrophilic  molecules  in  particular  are  believed  to  be  transported  by  the 
intercellular route and the presence of the contents of membrane-coating granules in 
the intercellular space  may inhibit penetration in both keratinized and non- 
keratinized mucosae. 
 
1.4.2 Dynamics: 
The oral mucosal absorption of drugs could be adequately described by 
first order rate process.  Several potential barriers to oral mucosa drug absorption 
have been identified. These   include the mucus layer, keratinized layer, intercellular 
lipid of epithelium, basement membrane and lamina propria. In addition, the 
absorptive membrane thickness, blood supply blood/lymph drainage, cell renewal 
and enzyme content will all contribute to reducing the rate and amount of drug 
entering the systemic circulation.  Dearden and Tomlison (1971) pointed out that 
salivary secretion alters the buccal absorption kinetics from drug solution by 
changing the concentration of drug in the mouth.  They proposed a linear 
relationship between salivary secretion and time thus:  where ‘m’ and ‘C’ are the 
mass and concentration of drug in mouth at time ‘t’, Vi, the volume of solution put 
into mouth cavity and ‘V’ is salivary secretion rate.
 
T Suzuki et al designed a new perfusion system to study oral mucosal 
absorption drug using salicylic acid as a model drug in oral perfusion medium. They 
proposed following three compartment models. 
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Cp, drug concentration in plasma; Cm, drug concentration in perfusion 
medium; Ka, first-order absorption rate constant; F, fraction of disappeared drug 
transferred to circulating  blood; K12  and K21, first order transfer rate constants 
between   two   compartment   K10     first   order  elimination   rate   constant:   Vdc 
distribution volume of control compartment; Vdt  distribution volume of peripheral 
compartment. 
 
1.5 FACTORS AFFECTING BUCCAL ABSORPTION:      (Bhalodia R.et al., 2010) 
 
The oral cavity is a complex environment for drug delivery as there are 
many   interdependent and independent factors which reduce the absorbable 
concentration at the site of absorption. 
 
1.5.1   Membrane Factors: 
 
This i n v o l v e s    degree   of   keratinization,   surface   area   available   for 
absorption, mucus layer of salivary pellicle, intercellular lipids of epithelium; 
basement membrane and lamina propria.  In addition, the absorptive membrane 
thickness, blood supply/ lymph drainage, cell renewal and enzyme content will all 
contribute  to  reducing  the  rate  and  amount  of  drug  entering  the  systemic 
circulation. 
 
1.5.2 Environmental Factors: 
1.5.2.1 Saliva:  The  thin  film  of  saliva  coats  throughout  the  lining  of  buccal 
mucosa and is called salivary pellicle or film.  The thickness of salivary film is 
0.07 to 0.10 mm.  The thickness, composition and movement of this film effects 
buccal absorption. 
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1.5.2.2 Salivary glands: The minor salivary glands are located in epithelial or 
deep epithelial region of buccal mucosa. They constantly secrete mucus on surface 
of buccal mucosa.  Although, mucus helps to retain mucoadhesive dosage forms, it 
is potential barrier to drug penetration. 
 
1.5.3 Movement of oral tissues: 
 
Buccal region o f  oral cavity shows less active movements. The 
mucoadhesive polymers are to be incorporated to keep dosage form at buccal 
region for long periods while withstanding tissue movements during talking and if 
possible during eating food or swallowing. 
 
1.6 ADVANTAGES OF BUCCAL ABSORPTION: (Bandyopadhyay A. K., 2008)                                                                                         
The oral mucosa has a rich blood supply.   Drugs are absorbed from the 
oral cavity through the oral mucosa, and transported through the deep lingual or 
facial  vein,  internal  jugular  vein  and  braciocephalic  vein  into  the  systemic 
circulation.  Following buccal administration, the drug gains direct entry into the 
systemic circulation thereby bypassing the first pass effect. Contact with the 
digestive fluids of gastrointestinal tract is avoided which might be unsuitable for 
stability of many drugs like insulin or other proteins, peptides and steroids.   In 
addition, the rate of drug absorption is not influenced by food or gastric emptying 
rate. 
 
 
The area of buccal membrane is sufficiently large to allow a delivery 
system to be placed at different occasions, which may be advantageous if the drug 
delivery system or other excipients reversibly damage or irritate the mucosa. 
Additionally, there are two areas of buccal membranes per mouth, which would 
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allow buccal drug delivery systems to be placed, alternatively on the left and right 
buccal membranes. 
 
There is good accessibility to the membranes that line the oral cavity 
which makes application painless and without discomfort, precise dosage form 
localization possible and facilitates ease of removal without significant associated 
pain and discomfort.  Thus, patients can control the period of administration or 
terminate delivery in case of emergencies.  The oral mucosal route has in the past 
exhibited better patient compliance than either the vaginal or rectal route of drug 
administration thus it would be anticipated that novel buccal dosage forms would be 
well accepted by patients.  In addition, the route is not gender specific as is the case 
with vaginal route. 
The oral mucosa is routinely exposed to a multitude of different foreign 
compounds and physical insult.  So it has evolved a robust membrane that is less 
prone to irreversible damage by drug, dosage form or additives used therein. 
Thus, it may be feasible to include permeation enhancers in the formulation to 
increase systemic availability of the drug without observing permanent damaging 
effects. 
 
 
Due to some therapeutic reasons oral cavity is the only ultimate route for drug 
delivery, for example, for those patients nil by-mouth, if either nausea or vomiting 
is a problem, if the patient is unconscious, in patients with an upper 
gastrointestinal tract disease or surgery, which affects gastrointestinal absorption or 
patient groups, which have difficulty in swallowing peroral medications e.g., very 
young and elderly. 
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Additional advantages  of  the  oral  cavity  as  a  site  for  systemic  drug 
delivery  include:  sterile  techniques  are  not  required  during  manufacture  or 
administration, the oral  cavity contains teeth upon which drug delivery systems 
can be physically attached using  dental  adhesives, the oral mucosa is low in 
enzyme activity and enzymatic degradation is  relatively slow, hence, from the 
point of drug inactivation, the oral musocal route would be preferred to the nasal or 
rectal routes. 
 
1.7 LIMITATIONS IN BUCCAL ABSORPTION:  
(Bhalodia R.et al., 2010) 
 
• The area of absorptive membrane is relatively smaller.  If the effective 
area for absorption was dictated by the dimensions of a delivery system, 
this area then becomes even smaller. 
• Saliva is continuously secreted into the oral cavity diluting drugs at the site 
of absorption resulting in low drug concentrations at the surface of the 
absorbing membrane. In voluntary swallowing of saliva results in a 
major part of dissolved  or  suspended  released
  drug  being  removed  
from  the  site  of absorption. Furthermore, there is risk that the delivery 
system itself would be swallowed. 
• Drug characteristics may limit the use of the oral cavity as a site for 
drug delivery. Taste,   irritancy, allerginicity and adverse properties such as 
discoloration or erosion of the teeth may limit the drug candidate list for 
this route.  In addition, the drug should not adversely effect the natural 
microbial flora of the oral cavity. 
• Conventional type of buccal drug delivery systems did not allow the patient 
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to concurrently eat, drink or in some cases, talk. 
• The permeability of the oral mucosa is not great compared to other 
mucosal membranes. 
 
1.8 BUCCAL DOSAGE FORMS:           (Bhalodia R.et al., 2010)   
 
Buccal Dosage forms are meant to be placed between gingiva and cheek. 
 
 
 
1.8.1  Conventional Dosage Form: 
The conventional type of buccal dosage forms are buccal tablets, troches 
and lozenges, and mouth washers.  Buccal tablets are small, flat, oval tablets and are 
intended to be held between the cheek and the teeth or in the cheek pouch (buccal 
tablets). Progesterone tablets can be administered this way.  These tablets should be 
designed not to disintegrate but to slowly dissolve, typically over a 15 to 30 
minutes period to provide for effective absorption.   Troches and lozenges are two 
other types of tablets used in oral cavity where they are intended to exert a local 
effect in the mouth or throat.  These tablet forms are commonly used to treat sore 
throat or to control coughing in common cold.  Lozenges (pastiles or cough drops) 
are usually made with the drug incorporated in a flavored, hard-candy sugar base.  
Lozenges may be made by compression but are usually formed by fusion or by a 
candy – moulding process. Troches, on the other hand, are manufactured by 
compression as are other tablets.  These two classes of tablets are designed not to 
disintegrate in the mouth but to dissolve or slowly erode over a period of perhaps 30 
minute or less.   A mouth wash is an aqueous solution, which is most often used 
for its deoderant, refreshing or antiseptic effect on buccal mucosa. 
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1.8.2 Advanced Buccal Dosage Forms: 
 
The novel type buccal dosage forms include buccal adhesive tablets, 
patches, films, tapes, semisolids (ointments and gels) and powders. 
 
1.8.2.1 Mucoadhesive Tablets: 
Buccal mucoadhesive tablets are dry dosage forms that move to be moistened 
prior to placing in contact with buccal mucosa.  A double layer tablets, consisting of 
adhesive matrix layer of hydroxy propyl cellulose and poly (acrylic acid) with an 
inner core of cocoa  butter containing insulin and a penetration enhancer (sodium 
glycocholate) has been described by Wagai.  The two buccal adhesive tablets 
commercially available in UK are “buccastem” (Prochlor perazine maleale) and 
“Suscard Buccal” (glyceryl trinitrate). 
 
 
 
 
1.8.2.2 Patches, Tapes & Films: 
 
 Buccal patches consists of two ply laminates, with an aqueous solution of 
the adhesive polymer being cast onto an impermeable backing sheet, which was 
then  cut  to  the  required  oval  shape. A novel mucosal adhesive film called 
“Zilactin” – consisting of an alcoholic solution of hydroxy propyl cellulose and 
three organic acids, forms a film which applied to the oral mucosal surface which 
can be retained in place for at least 4 hours, even where challenged with fluids. 
 
1.8.2.3 Semisolid Preparations (Ointments and Gels): 
 
 Bioadhesive gels or ointments have less patient acceptability than solid 
dosage adhesive forms, and most are used only for localized drug therapy within 
the oral cavity. One of  the original oral mucosal-adhesive delivery systems 
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“orabase” consists of finely ground pectin, gelatin and sodium carboxy methyl 
cellulose dispersed in a poly (ethylene) and a mineral oil gel base, which can be 
maintained at its site of application for 15-150 minutes. 
 
1.8.2.4 Powders: 
Yam moto et al have described   a   hydroxpropyl   cellulose   and 
beclomethasone-diproprionate containing powder that was sprayed onto the oral 
mucosa of rats.   A significant increase in the residence time relative to an oral 
solution was seen, and 2.5% of beclomethasone was retained on buccal mucosa 
for over 4 hours. 
 
 
 
1.9 DESIGN OF BUCCAL MUCOADHESIVE PATCHES: 
                                   (Bandyopadhyay A. K., 2008; Mathiowitz E., 2009) 
 
1.9.1 Different Components of Buccal Mucoadhesive Patches: 
 
The different components of buccal mucoadhesive  patches are as following: 
• Drug 
 
• Polymers (bio adhesive polymers, polymers controlling rate of release 
and polymers to prepare backing membrane). 
• Backing membrane. 
 
• Plasticizer 
 
• Penetration enhancer. 
 
 
 
1.9.2 Profile of Each component: 
 
All the above ingredients are discussed in detail, as follows: 
 
1.9.2.1 Drug:  
The important drug properties that affect its diffusion through the patch as 
well as the buccal include molecular weight, chemical functionality and melting 
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point.  The selection of a suitable drug for design of buccal mucoadhesive drug 
delivery system should be based on pharmacokinetic properties.  Following are the 
critical properties for candidature to buccal mucoadhesive drug delivery. 
• The conventional single dose of drug should be low. 
 
• Through oral route, the drug may exhibit first pass effect or presystemic 
drug elimination.The fraction of oral bioavailability F i s  l o w  ( F<0.5 i n  
comparison to IV dose) and liver extraction ratio (ER) is high (ER>0.7). 
• Drug absorption should be passive when given orally. 
 
 
 
• The drug should not adversely affect the natural microbial flora or oral 
cavity. 
 
• Drug should not have bad taste and be free from irritancy, 
allergenicity and discoloration or erosion of teeth. 
• The drug must be appreciably absorbed via buccal mucosa as 
evaluated by buccal absorption test. 
 
1.9.2.2 Polymers:                                                 (Bandyopadhyay A. K., 2008) 
 
In buccal mucoadhesive patches, three different categories of 
polymers differing functionally are used.  These are as follows: 
• Bioadhesive polymers. 
• Polymers controlling rate of release of drug from matrix. 
• Polymers used to prepare backing membrane. 
Each one of this will be discussed as follows: 
 
1.9.2.3 Bioadhesive  polymers: These  are  hydrophilic  macromolecules  that 
contain  numerous  hydrogen  bond  forming  groups.These polymers become bio 
adhesive on hydration and are therefore called “wet adhesives”. 
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The characteristic properties of ideal bio adhesive are: 
 
• It should have good mucoadhesive property and at the same time it 
should be innocuous to buccal mucosa. 
• It should  not  chemically  react  with  the  drug  and  other  excipients  
in Formulation. 
 
• Molecular weight, glass transition temperature and chemical 
functionality of polymer must allow proper diffusion and release of drug. 
• It should be pharmacologically bland-free from irritancy, allergenicity, 
bad taste and adverse properties such as discoloration or erosion of 
teeth.  Cost of polymer should not be excessive. 
Examples of good bio adhesive polymers include Hydroxy propyl cellulose 
(HPC), Hydroxy propyl methyl cellulose (HPMC), carbopol 934p, gelatin, pectin, 
PVP  44,000,  sodium  alginate,  hydroxyethyl  cellulose,  PEG  6000,  tragacanth, 
Gantrez-AN,   methyl   cellulose,   carboxy   methyl   cellulose,   sodium  carboxy 
methylcellulose, Gantrez AN-139, starch, chitosan and diethylaminoethyl dextran. 
 
 
1.9.2.4 Polymers controlling rate of release of drug from 
buccal mucoadhesive patches: 
  The polymers which are insoluble in saliva or water can be used as efficient 
matrix systems through which rate of release of drug can be controlled as desired.  
Examples for this category include ethylcellulose and butyl rubber.   Water-soluble 
polymers can be used for controlling rate of release in which, rate of polymer 
dissolution will be release rate determining step. 
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1.9.2.5 Polymers used to prepare backing membrane:   
 The polymer whose solution can be casted into thin poreless uniform water 
impermeable film can be used to prepare backing membrane of patches.  It should 
have good flexibility and high tensile strength and low water permeation. They 
should be stable on long storage maintaining their initial physical properties per se.  
The cellulose acetate in concentration of 2.4% w/v in acetone with 10% of 
plasticizer (PEG 4000 or glycerol) of total polymer weight when air dried produces 
a thin film suitable for backing membrane purpose.  Similarly, 2-4% w/v solution of 
ethyl cellulose in 1:4 mixture of alcohol: toluene and suitable plasticizer can be 
casted into film. 
The backing membrane can be of two types: 
• A polymer solution casted into thin film.  It is biodegradable in nature. 
• A polyester laminated paper with polyethylene.  It is not biodegradable. 
 
 The main function of backing membrane is to provide unidirectional drug 
flow to buccal mucosa.  It prevents the drug to be dissolved in saliva and hence 
swallowed avoiding the contact between drug and saliva.  The material used for 
the backing membrane must be inert and impermeable to drugs and penetration 
enhancers.  The thickness of the backing membrane must be thin and should be 
around 75-100 microns. The most commonly used backing   materials are 
polyester laminated paper with polyethylene.  Other examples include cellophane-
325, multiphor sheet and polyglassine paper. 
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1.9.2.6 Plasticizer: 
These are the materials used to achieve softness and flexibility of thin 
films of polymer or blend of polymers.  Examples of common plasticizers used 
are glycerol, propylene glycol, PEG 200, PEG 400, castor oil etc.   Usually the 
percentage of polymer falls in the range of 10-50% of total polymer weight.  The 
plasticizers help in release of the drug substance from the polymer base as well as 
act as penetration enhancers. The choice of the plasticizer depends upon the ability 
of plasticizer material to solvate the polymer and alters the polymer – polymer 
interactions. When used in correct proportion to the polymer, these materials 
impart flexibility by relieving the molecular rigidity. 
 
 
1.9.2.7 Penetration Enhancers: 
 The  use  of  penetration  enhancers  such  as  sodium  lauryl  sulphate, 
cetylpyridinium chloride, azone and capsaicin has been investigated as a suitable 
method for  improving the penetration of non-peptide drugs through the buccal 
mucosa.  Other effective penetration enhancers are sodium taurocholate, sodium 
deoxycholate, sodium methoxysalicylate, sodium dextransulphate and EDTA. 
Because all penetration enhancers perturb membrane integrity, it is inevitable that 
varying extents of insult will occur to the contacting membranes. Bile salts, 
laureth-9 and acylarnitines show a direct relationship between the degree of tissue 
damage and the extent of absorption promotion.  In general, non-surfactant like 
enhancer appear to produce fewer morphological changes than their surfactant 
Counterparts. 
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1.10 Theories of Bioadhesion/ Mucoadhesion:                   (Mathiowitz E., 2009) 
 Mucoadhesion is proposed to occur in three stages. Initially, an intimate 
contact must form between the mucoadhesive and mucus (i.e., they must “wet” each 
other) then the mucus/ mucoadhesive macromolecules interpenetrate and finally the 
molecules interact with each other by secondary non-covalent bonds.   The bonding 
occurs chiefly through both physical and chemical interactions.  Physical or 
mechanical bonds result from entanglement of the adhesive material and the 
extended mucus chains. Secondary chemical bonds may be due to electrostatic 
interactions, hydrophonic interactions, hydrogen bonding and dispersion forces.  
Covalent bonding, such as Occurs with cyanoacrylates, is also possible for 
Mucoadhesion but is not yet common in pharmaceutical systems.  Several theories 
of bioadhesion have been proposed to explain fundamental mechanism(s) of 
attachment. In a particular system one  or  more  theories  can  equally  well  
explain  or  contribute  to  the formation   of   bioadhesive   bonds   various   
theories   propounded   to   explain mucoadhesion/ bioadhesion are: 
• Wetting theory. 
 
• Electronic theory 
 
• Adsorption theory 
 
• Diffusion theory 
 
• Fracture theory. 
 
 
 
1.10.1 Wetting Theory: This theory best describes the adhesion of liquid or paste 
to a biological surface.  The work of adhesion can be expressed in terms of surface 
and interfacial tension (γ) being defined as the energy per cm² released when an 
interface is formed.  According to Dupre’s equation the work of adhesion is given by: 
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 Wa = γA + γb – γB …1 
 
Where  the  subscript  A  and  B  refer  to  the  biological  membrane  and  the 
bioadhesive formulation respectively.  The work of cohesion is given by: 
 We = 2γA = 2γB …2 
 
For a bioadhesive material B spreading on a biological substrate A the spreading 
coefficient is given by: 
 SB/A = γA – (γB + γAB) …3 
 
 
SB/A   should be  positive  for  a  bioadhesive  material  to  adhere  to  a  biological 
membrane.  For a bioadhesive liquid B adhering to a biological membrane A the 
contact angle is given by: 
 Cos φ – (γA – γAB / γB) …4 
 
 
 
1.10.2 Diffusion Theory:  
 Voyutski appears to be the first to discuss diffusion as a theory for adhesion.   
According to this theory the polymer chains and the mucus co-mingle to a 
sufficient depth to create a semi-permanent adhesive bond. The polymer chains 
penetrate the mucus; the exact depth to which it penetrates to achieve s u f f i c i e n t  
Mucoadhesion depends on   diffusion coefficient, time o f  contact, and other 
experimental variables.  The diffusion coefficient depends on molecular weight and 
decreases rapidly as the cross-linking density increases. The molecular weight, chain 
flexibility, expanded nature of the mucoadhesive and substrate as well as similarity 
in chemicals structure is required for good mucoadhesion. 
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1.10.3 Electronic theory:  
According to this theory electron transfer occurs on contact of adhesive 
polymer and the mucus glycoprotein network because of difference in their 
electronic structure.  This results in the formation of electrical double layer at the 
interface.  Adhesion occurs due to attractive forces across the double layer.  The 
electronic theory of adhesion was suggested by Derjaguin and Smigla. 
 
 
1.10.4 Fracture T h e o r y :   
The fracture theory of adhesio n  i s  r e l a t e d  t o  separation of two surfaces 
after adhesion.  The fracture strength is equivalent to adhesive strength as given by: 
L
Eε
σ =  
where E is young’s modulus of elasticity, ε is the fracture energy and L is 
the critical crack length when two surfaces are separated.  The work of fracture of an 
elastomer network Gc is given by: 
K McGc =  
 
 
K is a constant dependent on the density of the polymer, effective mass, 
length and flexibility of a single mucin chain bond and bond dissociation energy.  Gc 
of an  elastomeric  network  increases  with  molecular  weight  Me  of  the  network 
stands. 
 
1.10.5 Adsorption Theory:  
 Adsorption theory has been described by Kembell and Hantsherger.  
According to this theory after an initial contact of two surfaces the material will 
adhere because of surface forces acting between the atoms in the two surfaces. 
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 Weak interaction of Vander Wall type plays an important role. However, if 
adsorption is due to chemical bonding i.e., chemisorption, then ionic, covalent and 
metallic bonds play an important role at the interface. 
From a  drug  delivery  point  of  view  the  mechanism  of  mucoadhesion 
appears  best  explained  by  a  combination  of  diffusion  and  electronic  theory, 
although other mechanisms  may simultaneously be operative at minor level.   It may 
also be more appropriate to restrict the term “mucoadhesion” to describing the  
adhesion  of  hydrated  dosage  forms  to  those  mucus  membranes  having  a 
substantial mucus layer.  The term “bioadhesion” or “mucosal adhesion” may be 
more suitable to describe adhesion to the mucosal of the oral cavity. 
 
 
1.11 FACTORS INFLUENCING BIOADHESION: (Bandyopadhyay A. K., 2008) 
 
1.11.1 Physico-Chemical Parameters: 
 
pH: pH influences the charge on the surface of both mucus and the polymer.  
The charge density of both mucus and the polymer are influenced by pH, which in 
turn affects mucoadhesion.   Degree of hydration.   Depending on the degree of 
hydration adhesion properties will be different.  It is maximum at certain degree of 
hydration.  When the degree of hydration is high, adhesiveness is lost probably due 
to formation of slippery, non-adhesive mucilage in an environment of a large 
amount of water at or near the interface. 
 
1.11.2 Structural Properties: 
 
1.11.2.1 Molecular weight and polymer chain length: High molecular weight 
polymers are generally preferred over low molecular polymers for mucoadhesion. 
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1.11.2.2 Spatial conformation: Despite a high molecular weight of 19,500,000 
for dextrans they have similar adhesive strength to that of polyethylene glycol with 
a molecular weight 200,000.  The helical conformation of dextran may shield any 
adhesively active groups, primarily responsible for adhesion, unlike PEG Polymers 
which have linear conformation. 
 
1.11.2.3 Molecular f l e x i b i l i t y :  High molecular flexibility produces greater 
bioadhesion. 
 
1.12.2.4  Chemical  structure:  Hydrogen  bonding  due  to  the  presence  of 
hydrophilic   groups  such  as  –COOH  or  –OH  plays  a  significant  role  in 
mucoadhesion. The strongly anionic polyelectrolyte particularly those with a high 
charge density of –COOH or –OH functionality are better candidates for 
bioadhesion than neutral molecules. 
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2. LITERATURE SURVEY  
 
2.1. Literature Review: 
Recent Advancements in Mucoadhesive Drug Delivery Systems: 
         
Ananta Choudhury., et al. (2009)   Designed  a  sustained  release  films  of 
ciprofloxacin hydrochloride  using different concentration of HPMC and PVA and 
evaluated for different parameters also in-vitro and ex-vivo drug release study, and 
release kinetic behavior.  From the results concluded that all the prepared films 
having desire flexibility and mucoadhesive properties, good in-vitro and ex-vivo 
drug release performance. It was also concluded that in respect to mucoadhesion 
time,   mucoadhesion   strength   study   and   in-vitro   drug   release   study   the 
performance of films composed of HPMC gives better results as compare to the 
films composed of PVA. 
 
      
  
Attama   AA.,   et al. (2008)   Formulated   novel   buccoadhesive   patches   of 
hydrochlorothiazide using EC and HPMC by solvent casting method. The patches 
were evaluated for different parameters. The result of the study indicated that 1:2 
ratios of EC and HPMC gave the highest buccoadhesive strength. The area swelling 
ratio indicated that the patches did not swell up to two times their initial areas, with 
the batch containing 3:2 ratios of EC and HPMC possessing the highest area 
swelling ratio. Higuchi analysis of the release mechanism indicated that the release 
of HCTZ from the patches formulated with 1:1 and 2:1 ratios of EC and HPMC 
predominantly occurred by a diffusion process.   
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           Biswajit Basu., et  al . (2010)   Formulated mucoadhesive buccal  patches  
of pimozide by using HPMC (15 and 47cps) carbopol 934, PVA, and PVP. The 
patches were evaluated for different parameters. The data of in vitro release from 
patches were fits into Hixon-Crowell, Higuchi and Korsmeyer-Peppas models. In-
vivo studies in rabbits showed 85.97% of drug absorption from HPMC (15cps) patch 
in 60 min 
 
          Dhahrni S., et al. (2010) Design and evaluated mucoadhesive buccal patches 
of   ondensetron HCl by solvent casting technique using HPMC-E15 as mucoadhesive  
polymer.  The patches were evaluated for weight variation, thickness, surface pH, 
moisture absorption, in-vitro residence time, mechanical properties, in-vitro release, 
ex-vivo permeation studies   and   drug   content uniformity and got the better results 
and obey first order kinetics. 
 
Giradkar KP., et al. (2010) Deigned the polymeric films of tizanidine 
composed different proportions of NaCMC and CP 934 by solvent casting method, 
glycerol was used as plasticizer.  Films were evaluated for different parameters It 
was concluded that NaCMC and CP-934(60:40) showed moderate drug release for 
8 hrs. Increase in CP934 concentration resulted in decreasing the swelling index and 
surface pH. The mucoadhesive strength and in-vitro residence time is slightly 
increased beyond 30%concentration of Carbopol 934.
    
        
Goudanavar PS., et al. (2010) Developed mucoadhesive buccal films of 
glibenclamide with HPC, PVP, and EC polymer combination, by solvent casting 
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technique and evaluated for number of parameters. The results revealed that the 
release of drug is depended on the polymer type as well as on their concentration. 
Film containing HPC alone released the maximum drug. Incorporation of PVP or 
EC reduced the release rate of Glibenclamide from the buccal film.  
 
Koland ., et al. (2009)   Formulated  and  evaluated  fast  dissolving  films  
of ondensetron hydrochloride for sublingual administration by PVA, PVP, Carbopol-
934 in different ratios, propylene glycol or PEG 400 as plasticizers and mannitol as 
sweeteners. Films evaluated for different parameters and bioadhesive strength. 
Concluded that use of water soluble sweeteners especially mannitol increases 
taste, also increases in drug release and drug permeation. 
 
            Manish., et al. (2010) Developed mucoadhesive buccal films of famotidine 
using HPMC, NaCMC and PVA by solvent casting method. The films were 
evaluated for their physical characteristics. Good results were obtained both in-vitro 
and in-vivo conditions for famotidine films. The results can be extrapolated to the 
human beings as the structure and permeability of buccal membrane of rabbits is 
similar to that of human beings. Hence the development of  bioadhesive buccal 
formulations for famotidine may be a promising one as the dose of  famotidine may 
be decreased and hence side effects may be reduced. 
 
     Nappinnai M., et al. (2008)  Formulated buccal films of nitrendipine by using 
different  polymers  like  HPMC  K100,  HPC,  NaCMC,  Sodium alginate,  PVA, 
PVP K-30 and  carbopol-934 were used. The films were evaluated for different 
parameters and ex-vivo permeation. From results, it was concluded that buccal films 
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of HPMC and NaCMC showed moderate drug release and satisfactory film 
characteristics, selected as best formulation. 
              Padmaja Chimmiri .,et al. (2012)  were prepared Controlled released buccal 
films of Tramadol Hydrochloride and investigated using polymers HPMC K4M, 
sodium carboxy methyl cellulose, carbopol 934 in different ratios. Compatibility 
studies were done by using Fourier Transform Infrared Spectroscopy (FTIR) and 
Differential Scanning Calorimetry techniques (DSC). FTIR spectra and DSC 
thermograph of Tramadol Hydrochloride, polymers, and all formulations indicates 
that there is no chemical interaction and confirmed the stability of the drug. The films 
were evaluated for their physical characteristics like weight variation, Thickness, 
folding endurance, surface pH, drug content uniformity, swellingindex, Ex vivo 
bioadhesion time. 
 
 . Raghvendra Rao NG., et al. (2011) Buccal films of montelukast were 
prepared using mucoadhesive polymers like HPMC (K4M), HPMC (50cps), HPMC 
(5cps), Eudragit  RL-100   and   PVP  K-30  by  solvent  casting  technique,  films  
were characterized for number of parameters and bursting strength, in-vitro drug 
release study.  All formulations follow zero-order kinetics as (r2) values are higher 
than that of first-order release kinetics.  Mechanism of drug release pattern was 
confirmed by Higuchi plots.  
 
 Satishbabu BK., et al. (2008)   Prepared bi laminated buccoadhes ive f i lm 
of  atenolol, by solvent casting technique. The mucoadhesive layer was composed of 
mixture of drug and sodium alginate with or without carbopol-934P and backing 
layer was made of EC, and films were evaluated for different parameters. The 
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results show that bilaminated films were flexible and having suitable toughness. 
Also, sodium alginate was easily laminated on ethyl   cellulose.  The study concludes 
that the addition of carbopol-934P increases the viscosity and swelling of films, 
thereby control the release of drug and improves the mucoadhesive properties. 
 
ShafiullahD., et al. (2006) Formulated mucoadhesive chlorhexidinebuccal 
films formulated  films were evaluated for compatibility, drug content, antibacterial 
activity against Escherichia coli and in-vitro release studies. In-vitro release studies 
for films should a higher rate of drug release for HPMC films compared to 
chitosan films. 
 
Shah Divyen., et al. (2010) Formulated mucoadhesive buccal films of 
lycopen using water soluble polymers by solvent casting technique, propylene glycol 
used as  plasticizer.  Films were evaluated for thickness, tensile strength, bending 
strength, film swelling and erosion properties, ex-vivo mucoadhesion time. It was 
concluded that formulation contains lower drug dose, sufficient for therapeutic 
effect, non-irritant, high mucoadhesion force and time required to dissolve is also 
high compare to other formulation.
  
 
 Surya N. Ratha Adhikari., et al. (2010) were prepared Buccal  patches  
for  the  delivery  of atenolol  using  sodium  alginate  with  various  hydrophilic 
polymers  like  carbopol  934 P, sodium  carboxymethyl  cellulose, and  
hydroxypropyl methylcellulose in various  proportions and  combinations were  
fabricated  by solvent  casting  technique.  Various  physico- mechanical   
parameters  like  weight  variation,   thickness,   folding  endurance,  drug  
 Mucoadhesive Buccal Patches of Tramadol HCl Literature Survey 
 
Adhiparasakthi College of Pharmacy, Melmarvathur. Page 34 
 
content, moisture content,  moisture  absorption, and various ex vivo 
mucoadhesion parameters like mucoadhesive strength,  force of adhesion,  and 
bond strength  were evaluated. 
 
Thimmasetty J ., e t al. (2008)   Prepared mucoadhesive  buccal  patches  of 
carvedilol using the polymer such as HPMC, carbapol-934, eudragit RL 100 and 
ethyl  cellulose. The formulated patches were evaluated for different parameters and 
in-vitro release studies were conducted for carvedilol loaded patches. Good results 
were obtained both in-vitro and in-vivo condition for carvedilol patches. The results 
can be extrapolated to the human beings as the structure and the permeability of 
buccal membrane of the rabbits is similar to that of human being.  
 
 Viram., et al. (2010) Formulated  buccal films of carvedilol by using 
polymers like  Eudragit  RL-100,  PVP,  HPMC,  NaCMC  and  Carbopol  934  in  
various combinations by  solvent casting technique, using plasticizer propylene 
glycol with and without penetration  enhancers like DMSO, Tween-60 and castor 
oil. In ex-vivo diffusion studies formulation were consisting DMSO which increase 
the drug permeability up to 15% given as the best formulation.  
 
Vishnu M. Patel., et al. (2007)    Designed   mucoadhesive   buccal   patches 
containing  propranolol hydrochloride using solvent casting method, by eudragit L-
100,  carbopol-934  and PVP K-30  polymers. Patches were evaluated for different 
parameters and ex-vivo mucoadhesive strength, in-vitro buccal permeation.  Results  
indicates that  the  high  amount of  carbopol  934  and  low amount of PVP K30 
favour the ex-vivo mucoadhesive strength of the patches but low amount of carbopol 
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934 and high amount of PVP K30 favour the dissolution rate  and swelling index of 
the patches.  
 
Wong  CF ., et al. (1999)   Prepared  controlled  release  buccal  patches  of 
metoprolol using eudragit incorporating HPMC, NaCMC and carbopol and were 
evaluated for  various physical properties and drug release kinetics. Insoluble, 
flexible, organic solvent-free, controlled release patches could be fabricated using 
Eudragit NE 40D as the base matrix. The drug release as well as the adhesive 
properties of the patches could be modified by   incorporating bioadhesive polymers. 
For the above purposes, Cekol 700 appeared to be the most suitable since it 
provided both satisfactory bioadhesion and a predictable rate of drug release. 
 
  
 
 
 
 
 
 
 
 
DRUG AND 
 
     EXCIPIENTS
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2.2 DRUG PROFILE: (www.rxlist.com/ Tramadol hydrochloride) 
 
TRAMADOL HYDROCHLORIDE: 
 
Chemically Tramadol hydrochloride is 2[(dimethyl amino) methyl]-1–(3– 
methyl phenyl) cyclohexane hydrochloride. It is a steroidal drug and it contains 
not less than 99.00 % and not more than 101 % of C21H30O2 calculated with 
reference to the dried substance 
Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Formula: C16H25NO2 
 
Molecular weight: 299.84 
 
CHARACTERS: 
 
Appearance: 
          White almost white, crystalline powder 
 
Solubility: 
 
Freely soluble in water, and methanol and practically insoluble in ethanol, 
acetone and in fatty oils. 
Melting point:  
180-184ºC. 
 
 
Specific rotation:  
+ 186 - +132, determined on a 1% solution in alcohol (95%). 
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PHARMACOKINETICS                                  
Absorption: 
Tramadol is almost completely absorbed. The bioavailability of a 100 mg dose is 
75%. The peak plasma concentrations of racemic Tramadol occur 2 hours after the 
dose. The peak plasma concentrations of M1 occur 3 hours after the dose is given. 
Steady state is realized 2 days after dosing Tramadol four times a day. Food does not 
impact the rate or extent of absorption. 
 
Half Life 
The half-life of the drug is about 5.5 hours and the usual oral dosage 
regimen is 50 to 100 mg every 4 to 6 hours with a maximum dosage of 400mg/day. 
 
Distribution: 
The volume of distribution was 2.6 L/kg in males and 2.9 L/kg in 
females. Tramadol binds to proteins about 20%. Saturation of plasma proteins is only 
of concern if one exceeds the recommended dosage. 
 
Metabolic reactions: 
Tramadol is extensively metabolised. The production of the only known 
active metabolite, M1 (mono-o-desmethylTramadol) is dependent on the CYP2D6 
isoenzyme of the cytochrome  P-450  enzyme  system  and  hepatic  impairment  
results  in  decreased metabolism  of  both  the  parent  compound  and  the  active  
metabolite.  Patients who metabolise drugs poorly via CYP2D6 may obtain 
reduced benefit from Tramadol due to reduced formation of M1. 
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Excretion : 
 
About 30% of Tramadol will be excreted in the urine unchanged. 60% of the 
drug will be excreted in the urine as metabolites. The rest is unidentified or is a 
metabolite which could not be extracted. Tramadol itself is eliminated via the liver. 
The half-life of Tramadol is 6.3 hours and the half-life of M1 is 7.4 hours. After 
repeated dosing of Tramadol, the half-life of Tramadol increased to about 7 hours. 
 
Mechanism of action: 
 
 Tramadol is a new synthetic, centrally acting analgesic agent. The 
mechanism of action of Tramadol has yet to be fully elucidated, but it is believed 
to work through modulation of the gamma-aminobutyric acid (GABA)ergic, nor 
adrenergic and serotonergic systems. Tramadol, and its metabolite, known as M1, 
have been found to bind to µ-opioid receptors thus exerting their effect on 
GABAergic transmission, and to inhibit   reuptake   of   5-hydroxytryptamine   (5-
HT)   and   noradrenaline.   The   second mechanism is believed to be important  
since the analgesic effects of Tramadol are not fully antagonized by the µ-opioid 
receptor antagonist naloxone. 
 
Uses: 
 
Tramadol is used to treat moderate to moderately severe pain and most types 
of neuralgia, including trigeminal neuralgia. It has been suggested that Tramadol 
could be effective for alleviating symptoms of depression, anxiety, and phobias 
because of its action on the noradrenergic and serotonergic systems. 
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CONTRAINDICATION: 
 
 
• Hypersensitivity to Tramadol or any of its components 
 
• Hypersensitivity to opioids 
 
• Patients acutely intoxicated with alcohol, hypnotics, narcotics, 
centrally acting analgesics, opioids or psychotropic drugs 
 
Precautions: 
 
 
• Acute abdominal conditions 
 
• Renal impairment (caution with immediate-release, extended-
release not recommended in severe renal impairment) 
• Hepatic impairment (caution with immediate-release, extended-
release not recommended) 
• Respiratory depression 
 
• Patients receiving anesthetic medications 
 
• Patients who consume alcohol 
 
 
Veterinary use: 
 
 
Tramadol is used to treat post-operative, injury-related, and chronic (e.g., 
cancer- related) pain in dogs and cats as well as rabbits, coatis, many small 
mammals including rats and flying squirrels, guinea pigs, ferrets, and raccoons. 
Tramadol comes in ampoules in addition to the tablets, capsules, powder for 
reconstitution, and oral syrups and liquids; the fact that its characteristic taste is 
not very bitter and can  be masked in food and diluted in water makes for a 
number of means of administration. No data that would lead to  a  definitive  
determination  of  the  efficacy  and  safety  of  Tramadol  in  reptiles  or 
amphibians is available at this time, and, following the pattern of all other 
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drugs, it Appears that Tramadol can be used to relieve pain in marsupials such as 
North American opossums,  Short-Tailed  Opossums,  sugar  gliders,  wallabies,  
and  kangaroos  among others. 
 
2.3 POLYMERPROFILE 
 
2.3.1SODIUM ALGINATE                          (Raymond C. Rowe., et al., 2003) 
  
 
Nonproprietary Names: 
 BP :  Sodium Alginate 
 PhEur :  Sodium Alginate 
 USP-NF :  Sodium Alginate 
Synonyms: 
Alginatosodico; algin; alginic acid, sodium salt; E401; Kelcosol;Keltone; 
natriialginas; Protanal; sodium polymannuronate. 
Chemical Name: 
Sodium alginate  
CAS Registry Number:  
[9005-38-3] 
Empirical Formula and Molecular Weight: 
Sodium alginate consists chiefly of the sodium salt of alginicacid, which is a 
mixture of polyatomic acids composed of residues of Dmannuronicacid and                     
L-guluronic acid. 
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Structural Formula: 
 
 
Functional Category 
Stabilizing agent; suspending agent; tablet and capsule disintegrates; 
 
Description 
Sodium alginate occurs as an odorless and tasteless, white to paleyellowish-
brown colored powder 
Colour :  pale yellowish-brown 
Odour : odorless. 
Taste : tasteless 
Texture  :  powder  
Acidity/alkalinity :  pH _ 7.2 (1% w/v aqueous solution) 
Solubility: 
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water 
mixtures in which the ethanol content is greater than 30%. Also, practically insoluble 
in other organic solvents and aqueous acidic solutions in which the pH is less than 3. 
Slowly soluble in water, forming a viscous colloidal solution. 
 
Stability and Storage Conditions: 
Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative humidities and a cool temperature. Aqueous solutions of sodium alginate are 
most stable at pH 4–10. Below pH 3, alginic acid is precipitated. A 1% w/v aqueous 
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solution of sodium alginate exposed to differing temperatures had a viscosity 60–80% 
of its original value after storage for2 years. Solutions should not be stored in metal 
containers. Sodium alginate solutions are susceptible on storage to microbial spoilage, 
which may affect solution viscosity. Solutions are ideally sterilized using ethylene 
oxide, although filtration using a 0.45 mm filter also has only a slight adverse effect 
on solution viscosity. Heating sodium alginate solutions to temperatures above 
70°Ccauses de polymerization with a subsequent loss of viscosity. Autoclaving of 
solutions can cause a decrease in viscosity, which may vary depending upon the 
nature of any other substances present. Gamma irradiation should not be used to 
sterilize sodium alginate solutions since this process severely reduces solution 
viscosity. Preparations for external use may be preserved by the addition of 0.1% 
chlorocresol, 0.1% chloroxylenol, or parabens. If the medium is acidic, benzoic acid 
may also be used .The bulk material should be stored in an airtight container in a cool, 
dry place. 
 
Incompatibilities: 
Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenyl mercuric acetate and nitrate, calcium salts, heavymetals, and ethanol in 
concentrations greater than 5%. Low concentrations of electrolytes cause an increase 
in viscosity but high electrolyte concentrations cause salting-out of sodium alginate; 
salting-out occurs if more than 4% of sodium chloride is present. 
 
Applications in Pharmaceutical Formulation or Technology: 
1. Sodium alginate is used in a variety of oral and topical pharmaceutical 
formulations. 
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2.  In tablet formulations, sodium alginate may be used as both a binder and 
disintegrates ;( 3) it has been used as a diluent in capsule formulations. 
3. Sodium alginate hasal so been used in the preparation of sustained-release oral 
formulations since it can delay the dissolution of a drug from tablets, capsules 
and aqueous suspensions. 
4.  The effects of particle size, viscosity and chemical composition of sodium 
alginate on drug release from matrix tablets have been described. 
5. In topical formulations, sodium alginate is widely used as a thickening and 
suspending agent in a variety of pastes, creams, and gels, and as a stabilizing 
agent for oil-in-water emulsions. 
6. Recently, sodium alginate has been used for the aqueous microencapsulation 
of drugs, in contrast with the more conventional microencapsulation 
techniques which use organic solvent systems. It has also been used in the 
formation of nanoparticles 
7. Sodium alginate is also used in cosmetics and food products; see table 2.1 
Table 2.1: Uses of sodium alginate 
USE CONCENTRATION (%) 
Pastes and creams 5-10 
Stabilizer in emulsions 1-3 
Suspending agent 1-5 
Tablet binder 1-3 
Tablet disintigrent 2.5-10 
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2.3.2HYPROMELLOSE (HYDROXYPROPYL METHYLCELLULOSE) 
 
(Raymond C. Rowe, et al., 2003) 
 
1. Nonproprietary Names 
 
BP      :          Hypromellose 
 
JP       :          Hydroxy propyl methylcellulose 
 
PhEur :          Hypromellosum 
 
USP    :          Hypromellose 
 
 
2. Synonyms 
 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxy propyl cellulose; Metolose; 
Tylopur. 
 
3. Chemical Name and CAS Registry Number 
 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
 
 
4. Molecular Weight 
 
10,000 – 1,500,000. 
 
5. Structural Formula 
 
 
 
Where R is H, CH3, or CH3CH (OH) CH2 
 
 
 
 
6. Functional Category 
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Coating agent, film-former, rate-controlling polymer for sustained release, 
Stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
 
7. Applications in Pharmaceutical Formulation or Technology 
 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, Hypromellose is primarily used as a tablet binder, in 
film- coating, and as matrix for use in extended-release tablet formulations. High-
viscosity grades may be used to retard the release of drugs from a matrix at levels 
of 10–80% w/w in tablets and capsules. Depending upon the viscosity grade, 
concentrations of 2-20% w/w are used for film-forming solutions to film-coat 
tablets. Hypromellose at concentrations 0.45-1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions. Lower-
viscosity grades are used in aqueous film- coating solutions, while higher-viscosity 
grades are used with organic solvents. 
8. Description 
 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
 
9. Typical Properties 
 
Acidity/alkalinity      :          pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 
Density (bulk)           :          0.341 g/cm3 
 
Density (tapped)       :          0.557 g/cm3 
 
Density (true)            :          1.326 g/cm3 
 
Melting Point            :          browns at 190 – 200°C; chars at 225 
230°C 
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Table :2.2 Various grades of hypromellose 
 
Methocel product USP 28 designation 
Nominal viscosity 
(mPa s) 
Methocel K100 Premium LVEP 2208 100 
Methocel K4M Premium 2208 4000 
Methocel K15M Premium 2208 15 000 
Methocel K100M Premium 2208 100 000 
Methocel E4M Premium 2910 4000 
Methocel F50 Premium 2906 50 
Methocel E10M Premium CR 2906 10 000 
Methocel E3 Premium LV 2906 3 
Methocel E6 Premium LV 2906 6 
Methocel E15 Premium LV 2906 15 
Metolose 60SH 2910 50, 4000, 10 000 
Metolose 65SH 2906 50, 400, 1500, 4000 
Metolose 90SH 2208 100, 400, 4000, 15 000 
 
 
 
Solubility 
It is soluble in cold water and forming a viscous colloidal solution, 
practically insoluble in chloroform and ethanol (95%) and ether. But it was soluble 
in mixtures of ethanol and dichloromethane, mixtures of methanol and 
dichloromethane and mixtures of water and alcohol. 
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Viscosity (dynamic) 
A wide range of viscosity types are commercially available. Aqueous 
solutions are  most commonly  prepared,  although  hypromellose  may  also  be  
dissolved  in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol 
content is less than 50% w/w. 
 
10. Stability and Storage Conditions 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the 
viscosity of solutions. Hypromellose undergoes a reversible sol–gel transformation 
upon heating and cooling, respectively. 
 
11. Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, Hypromellose will not complex with metallic salts. 
 
2.3.3 Carbopol 934                                     (Raymond C. Rowe, et al., 2003) 
 
 
Carbopol-934, a synthetic high molecular weight, non-linear polymer of acrylic 
acid cross-linked with polyalkenyl polyether with average molecular weight 3x106 
Daltons. It contains not less than 56% and not more than 68% of carboxylic acid 
(-COOH) groups. 
 
Synonym : Acritamer, acrylic acid polymer carboxy vinyl polymer. 
 
 
 
Non proprietary names : BP carbomer, USP carbomer 
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Chemical name : Carboxyl polymethylene 
 
 
 
Empirical formula : (C3H4O2) x (-C3H5-sucrose) y 
 
Structure:  
 
 
 
Category: Bioadhesive, emulsifying, suspending & viscosity enhancing 
agent, tablet binder and release-modifying agent. 
Description:  White, fluffy, acidic, hygroscopic powder with a slight 
Characteristic odour. 
 
Solubility: After neutralization with alkali hydroxides or amines, soluble in 
water, in ethanol (96%) and in glycerol. 
pH: 2.5-3.0 (1% aqueous solution) 
 
Glass transition temp: 100–105°C 
 
 
 
Melting point: decomposition occurs within 30 minutes at 260°C. 
 
Specific gravity: 1.41 
 
Viscosity:  Carbomers disappears in water to form acidic colloidal solutions 
of low viscosity which when neutralized produce highly viscous gels. 29,400 to 
39,400 cps at 25oC (0.5% neutralized aqueous solution) 
 
 
 
Stability and storage: 
 
Carbomers are stable, though hygroscopoic materials and can be 
heated at temperatures be low 104º for up to 2 hours without affecting their 
thickening efficiency. 
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Applications: 
 
It is used as thickening, emulsifying and gelling agent. It is used as a 
tablet binder and matrix forming agent in sustained-release formulations affording 
zero- to near-zero-order release. It is used as the bioadhesive component in 
mucoadhesive ointments, gels and tablets. 
Safety:    
Carbomers are regarded as non toxic and non-irritant. 
 
2.3.4  CARBOXYMETHYLCELLULOSE SODIUM:   
                                                                                    (Raymond C. Rowe,etal., 2003)    
 
 
1. Nonproprietary Names : 
 
BP : Carmellose sodium  
USP : Carboxy methylcellulose sodium. 
 
2. Synonyms : Akucell, Aquasorb, Balnose, Cellulose gum, 
 
CMC sodium, E466, Finn fix, Nymcel, SCMC, 
  
 
Sodium carboxy methylcellulose, Sodium 
cellulose glycolate, Sodium CMC, Tylose CB. 
 
3. 
 
Chemical Name : 
 
Cellulose, carboxy methyl ether, sodium salt. 
 
4. 
 
Molecular weight : 
 
Molecular weight is 90000-700000. 
 
5. 
 
Structural Formula  : 
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6. Functional Category: 
Coating agent, stabilizing agent, suspending agent, Tablet and capsule 
disintegrates.Tablet binder, Viscosity increasing agent, Water-absorbing agent. 
  7. Applications in pharmaceutical formulation or technology: 
• Carboxy methylcellulose sodium is widely used in oral and topical 
properties. 
• Higher concentrations, usually 3-6%, of the medium-viscosity grades are 
used to produce gels that can be used as the base for applications and 
pastes; glycols are often included in such gels to prevent them drying out. 
 
Table2.3 Uses of carboxy methylcellulose sodium 
 
 
Use Concentration (%) 
Emulsifying agent 0.25 – 1.0 
Gel-forming agent 3.0 – 6.0 
Injections 0.05 – 0.75 
Oral solutions 0.1 – 1.0 
Table binder 1.0 – 6.0 
 
8. Description : Carboxy methylcellulose sodium 
occurs as a white to almost white, 
odorless, granular powder. 
9. Typical properties : 
 
 
 
• Density (bulk): 0.52 g/cm3 
 
 
• 
 
• 
 
Density (tapped): 0.78 g/cm3 
 
Dissociation constant: pKa = 4.30 
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2.4EXCIPIENT PROFILE: 
2.4.1 Polyvinyl Alcohol:                 (Raymond C. Rowe, et al., 2003) 
     
Non Proprietory Name: 
USP : Polyvinyl alcohol 
Synonyms : Airvol, Elvanol, Vinyl alcohol polymer. 
 
Chemical name and  
CAS Registry Number :  Ethanol, homopolymer (9002-89-5).  
Molecular weight :  30000-200000. 
Structural formula : 
 
 
 
 
 
 
Functional category:  
Coating agent, non-ionic surfactant; viscosity – increasing agent. 
Description:  
PVA occurs as an odorless, white to cream colored granular powder.  
Typical Properties: 
• Acidity / alkalinity. 
 
• pH 5.0 – 8.0 (4% aqueous solution). 
 
 
Solubility:   
Soluble in hot or cold water, solubility in water increases as the molecular 
weight decreases PVA is practically insoluble in aliphatic, aromatic and 
chlorinated hydrocarbons, esters, ketones and oils. 
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2.4.2 Propylene Glycol:                               (Raymond C. Rowe, et al., 2003) 
Nonproprietary 
Names: 
BP :  Propylene glycol 
 
JP :  Propylene glycol 
 
PhEur :  Propylenglycolum 
 
USP :  Propylene glycol   
Synonyms :  1, 2Dihydroxypropane  
Empirical Formula :  C3H8O2 
Molecular Weight :  76.09 
 
Structural Formula: 
 
 
 
 
 
 
 
 
 
 
Functional Category: 
 
Antimicrobial   preservative,   disinfectant,  humectant,   plasticizer,   solvent, 
Stabilizer for vitamins, water-miscible cosolvent. 
Description : 
 Propylene glycol is a clear, colorless, viscous, practically odorless liquid with 
a sweet, slightly acrid taste resembling that of glycerin. 
Typical properties: 
• Autoignition temperature: 371°C 
• Boiling point: 188°C 
• Density: 1.038 g/cm3 at 20°C 
• Viscosity (dynamic): 58.1 mPa s (58.1 cP) at 20°C. 
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Solubility: 
 
Miscible  with  acetone,  chloroform,  ethanol  (95%),  glycerin,  and  water; 
soluble at 1 in 6 parts of ether; not miscible with light mineral oil or fixed oils, 
but will dissolve some essential oils. 
 
Stability and Storage Conditions: 
 
At cool temperatures, propylene glycol is stable in a well-closed container, 
but at high temperatures, in the open, it tends to oxidize, giving rise to products 
such as propion-aldehyde, lactic acid, pyruvic acid, and acetic acid.  Propylene  
glycol  is chemically  stable  when  mixed  with  ethanol  (95%),  glycerin,  or  
water;  aqueous solutions may be sterilized by autoclaving. 
 
Incompatibilities: 
 
Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
 
Safety: 
 
Propylene glycol is used in a wide variety of pharmaceutical formulations 
and is generally regarded as a relatively nontoxic material. Propylene glycol is 
rapidly absorbed from the gastrointestinal tract; there is also evidence that it is 
absorbed topically when applied to damaged skin. In topical preparations, 
propylene glycol is regarded as minimally irritant, although it is more irritant than 
glycerin. 
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Applications in Pharmaceutical Formulation: 
 
Propylene  glycol  has  become  widely  used  as  a  solvent,  extractant,  
and preservative in a variety of parenteral and nonparenteral pharmaceutical 
formulations. Propylene glycol is commonly used as a plasticizer in aqueous film-
coating formulations. 
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3. AIM AND OBJECTIVES 
 
 
The buccal route as an alternative to other traditional method of systemic 
drug administration is a subject of growing interest because of numerous 
advantages. It is well known that the absorption of therapeutic compound from the 
oral mucosa provide a direct entry of the drug into the systemic circulation, 
`therefore avoiding the first  pass  hepatic  metabolism  and  gastrointestinal   drug  
degradation  which  is associated  with  oral  administration. The oral  cavity is  
easily   accessible for self-medication and hence it is well accepted by patient, and 
it is safe since the device can be easily administered and even removed from the 
site of application, stopping the input of drug whenever desired. 
Drug like Tramadol hydrochloride has been selected as model drug because 
the drug has all the pharmacokinetics and physico-chemical properties required for 
controlled release. Tramadol hydrochloride has oral bioavailability 68 – 72 % and 
having elimination half-life of 5.5 - 7 hrs and having volume of distribution 2.6 L/kg 
in male 2.9 L/kg in female. The Tramadol hydrochloride is freely soluble in water. 
Therefore, in the present study an attempt will be made to formulate buccal 
dosage form of Tramadol hydrochloride using different polymers and an adjuvants to 
avoid hepatic first pass metabolism. 
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The main objective of the present investigation was the following: 
• To formulate buccal patches of Tramadol hydrochloride using various 
polymers like sodium alginate, hydroxy propyl methylcellulose, sodium 
carboxy methyl cellulose and carbapol 934. 
• To study the influence of drug polymer ratio on drug release 
• To evaluate the patches for their physical parameters like appearance, 
thickness, weight uniformity, folding endurance, drug content, surface pH, 
swelling   index. 
• To Conduct In vitro dissolution studies, Ex vivo permeation studies, In vitro 
residence time and stability studies.  
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4. PLAN OF WORK 
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5. MATERIALS AND EQUIPMENTS 
 
 
5.1MATERIALS USED 
 
Table 5.1: List of Polymers and Excipients with source  
 
S.No. Ingredients Supplier 
1 Tramadol hydrochloride 
APEX pharmaceutical limited, 
Chennai. 
2 Sodium alginate 
Dr. Reddys pharmaceuticals limited, 
Mumbai. 
3 Sodium carboxy methyl cellulose SD fine-chem limited, Mumbai. 
4 HPMC Griffon laboratories Pvt. Ltd., Mumbai. 
5 PVA Hi-media laboratories, Mumbai. 
6 Carbopol 934 SD fine-chem. limited, Mumbai. 
7 
Potassium dihydrogen 
orthophosphate 
Fischer scientific chemicals, Mumbai. 
8 Propylene glycol Fischer scientific chemicals, Mumbai. 
9 Sodium hydroxide Fischer scientific chemicals, Mumbai. 
 
Mucoadhesive Buccal Patches of Tramadol HCl Materials and Equipments 
 
 
Adhiparasakthi College of Pharmacy, Melmarvathur.                                      Page 60 
 
5.2EQUIPMENTS USED : 
Table 5.2: List of Equipments with model/make 
S.No Equipments Model/ Make 
1 Electronic balance Shimadzu BL-220H. 
2 Sonicator 2200MH, Soltech srl,  Soluzioni 
Tecnologirhe, Milano, Italy. 
3 Magnetic stirrer 1-MLH, remi equipments limited, 
vasai. 
4 Digital pH meter Elico scientifics-L1610, Mumbai. 
5 UV spectrophotometer Shimadzu-1700 Pharmaspec UV-
VISIBLE spectrophotometer. 
6 FTIR spectrophotometer Shimadzu S4008. 
7 Differential scanning calorimeter Shimadzu DSC 60 with DTA, Japan. 
8 Screw Gauge J S export Ambala cantt.133006 
9 Disintegration apparatus Inco Instruments, Mumbai 
11 Hot air oven Sheetal Scientific Industries, 
Bombay 
12 Incubator Malveran instruments, Malvern, UK. 
13 USP dissolution apparatus Labtech. 
14 Franz diffusion cell Fabricated as per specifications . 
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6. EXPERIMENTAL WORK 
 
 
6.1. PREFORMULATION STUDY 
 
Before formulating a product, the physical and chemical properties of a drug 
substance have undergone some preformulation testing. It is the first step in rational 
development of dosage form. 
 
6.1.1. Identification of drug 
 
 a) Identification by FTIR spectroscopy    (Skoog D.A., et al., 1996; IP, 2007)       
 
Tramadol hydrochloride discs were prepared by pressing the Tramadol 
hydrochloride with potassium bromide and the spectra in between 4000 to 500 cm-
1 was obtained under the operational conditions.  The absorption maximums in 
spectrum obtained with the substance being examined correspond in position and 
relative intensity to those in the reference spectrum represented in Table 9.1 and 
shown in Figure 9.1. 
b) Identification by melting point        (Moffat. et al., 2004)                                   
 
Melting point of the drug was determined by capillary tube method. 
 
6.1.2. Physicochemical parameters 
 
 a) Organoleptic properties             (Lachman L.,et al.,1991) 
The color, odor and taste of the drug were recorded using descriptive 
terminology. 
 
 b) Solubility study                  (Moffat. et al., 2004)                                               
 
It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a 
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therapeutic response. The solubility of drug was recorded by using various 
descriptive terminologies. The solubility profile was represented in Table 9.2. 
 
6.1.3. Analytical methods 
 
a) Determination of λ max                       (USP, 2009) 
The absorption maximum of the standard solution was scanned between 200-400 
nm regions on UV-Visible spectrophotometer. The absorption maximum obtained 
with the substance being examined corresponds in position and relative intensity to 
those in the reference spectrum. 
 
6.1.3.1. Development of standard curve of Tramadol hydrochloride:  
                                                                                            (IP, 2007;USP,2009) 
Preparation of Phosphate buffer (pH 6.8) 
Phosphate buffer (pH 6.8) was prepared according to I.P. 2007. Placed 50 ml 
of 0.2 M potassium dihydrogen phosphate in a 200 ml volumetric flask and 22.4 ml 
of 0.2M sodium hydroxide was added and volume was made upto required quantity 
with water.  
Preparation of 0.2M Potassium dihydrogen phosphate 
Dissolved 27.218 gm of potassium dihydrogen phosphate in water and made 
up to 1000 ml. 
Preparation of stock solution of with Tramadol hydrochloride pH 6.8 
Accurately weighed 50 mg of Tramadol HCl, was dissolved in little quantity 
of pH 6.8 and volume was adjusted to 50 ml with the same to prepared standard 
solution having concentration of 1000 µg/ml. From that 1ml is pippeted out and 
makes upto 10ml to obtaine a concentration of 100 µg/ml. 
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Procedure 
From the stock solution, aliquots of 0 .5, 1, 1.5, 2 and 2.5 ml were 
transferred  into 100  ml  volumetric  flasks  and  final  volume  was  made  upto  10 
ml  with   pH 6.8. Absorbance values of these solutions were measured against 
blank (pH 6.8) at 271.5 nm using UV-Visible spectrophotometer.  
Preparation of Phosphate buffer (pH 7.4) 
 
Phosphate buffer (pH 7.4) was prepared according to I.P. 2007. Placed 31.2 
ml of 0.2 M potassium dihydrogen phosphate in a 200 ml volumetric flask and 22.4 
ml of 0.2M sodium hydroxide was added and volume was made upto required 
quantity with water.  
Preparation of 0.2M Potassium dihydrogen phosphate 
Dissolved 27.218 gm of potassium dihydrogen phosphate in water and made 
up to 1000 ml. 
Preparation of stock solution of with Tramadol hydrochloride pH 7.4 
Accurately weighed 50 mg of Tramadol HCl, was dissolved in little quantity 
of pH 7.4 and volume was adjusted to 50 ml with the same to prepared 
standard solution having concentration of 1000 µg/ml. From that 1ml is pippeted 
out and makes up to 10ml to obtaine a concentration of 100 µg/ml. 
Procedure 
From the stock solution, aliquots of 0 .5, 1, 1.5, 2 and 2.5 ml were 
transferred into100  ml  volumetric  flasks  and  final  volume  was  made  up to  10 
ml  with  pH 7.4. Absorbance values of these solutions were measured against blank 
(pH 7.4) at 271.5 nm using UV-Visible spectrophotometer.  
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6.1.3.2. B) Determination of Percentage purity of Drug                   (USP, 2009) 
Accurately weighed 50 mg of Tramadol HCl was dissolved in little 
quantity of distilled water to get the concentration of 1mg/ml. The solution was 
pipetted out of about 0.5 ml to 3 ml and volume was made up with distilled water. 
From the above stock solution, the concentration and absorbance was observed. 
The absorbance was measured at 271.5 nm against the blank using by UV-
Visible spectrophotometer. The percentage purity of drug was calculated by using 
calibration curve method (least square method).  
 
6.1.4. DRUG EXCIPIENT INTERACTION STUDIES 
6.1.4. a) Determination of drug-polymer compatibility     (Aulton M.E.,et al.,2002) 
The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients. 
 
 
 
Schematic representation of compatibility studies 
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6.1.4. b) Fourier transform Infra-Red (FTIR) spectroscopy          (IP, 2007) 
FTIR study was carried out to check compatibility of drug with polymers. 
Fourier transform Infrared Spectrophotometer was determined by using KBr 
dispersion method. The base line correction was done using dried potassium 
bromide. Then the spectrum of dried mixture of Tramadol HCl and potassium 
bromide was run followed by Tramadol HCl with various polymers by using FTIR 
spectrophotometer. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in 
the reference spectrum was represented. 
 
6.1.4. c) Differential scanning calorimetry (DSC)        (AultonM.E., et al.,2002) 
 
Any possible drug polymer interaction can be studied by thermal analysis. 
The DSC study was performed on pure Tramadol HCl, Tramadol HCl + HPMC, 
Tramadol HCl + carbopol-934 , Tramadol HCl + sodium alginate and Tramadol 
HCl + NaCMC. The 2 mg of sample were heated in a hermetically sealed 
aluminum pans in the temperature range of 25-300ºC at heating rate of 10ºC /min 
under nitrogen flow of 30ml/min. 
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7. FORMULATION OF MUCOADHESIVE BUCCAL PATCHES 
 
 
Table 7.1: Composition of mucoadhesive buccal patches of  Tramadol 
hydrochloride 
 
FORMU-
LATIONS        
TRAMADOL 
HCl 
(mg) 
SA 
(mg) 
HPMC 
(mg) 
CP 934 
(mg) 
NaCMC 
(mg) 
PROPYLENE 
GLYCOL 
% 
DISTILLED 
WATER 
(ml) 
F1  50  900  100  -  -  10  40  
F2  50  800  200  -  -  10  40  
F3  50  700  300  -  -  10  40  
F4  50  900  -  100  -  10  40  
F5  50  800  -  200  -  10  40  
F6  50  700  200  100  -  10  40  
F7  50  700  100  200  -  10  40  
F8  50  700  200  -  100  10  40  
F9  50  600  100  -  300  10  40  
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PREPARATION OF MUCOADHESIVE BUCCAL PATCHES BY SOLVENT 
CASTING METHOD:   (surya N. Ratha Adhikari .,et al.,2010) 
       The Buccal Patches were preferably formulated using the solvent casting method. 
The Required quantity of polymer was added in small quantities and mixed well to 
dissolved in distilled water. Drug dissolved in the above solution in small quantities.  
Plasticizer added to the above solution  and  mixed  well. Solution was then poured 
into petridishes and kept in hot air oven for drying at 40˚ C. After drying patches were 
removed with the help of sharp blade and kept in desicator for 24 hrs then cut into 
pieces of the desired shape and size. 
 
STEPS INVOLVED IN PREPARATION 
• Backing membrane was casted by pouring 4% w/v aqueous solution of PVA 
on aluminum foil in 9 cm petridishes at 42°C and left for 10 h. Phosphate 
buffer saline, pH 6.8, was used as solvent in the casting method. 
• A series of buccal   patches   composed   of   different ratios and combinations 
of polymers were prepared by solvent casting technique. 
•  Propylene glycol was incorporated as a plasticizer & penetration enhancer at a 
concentration of 10% w/w of dry weight of   polymers.  
• Fifty milligrams of Tramadol HCl was incorporated in mixtures containing 
different ratios and combinations of polymers and plasticizer.  The matrices 
were prepared by pouring 40 ml of the homogeneous solutions on the PVA-
aluminum foil backing membrane. Then, these buccal patches were dried at 
42°C in an incubator.  After 24 h, the  dried  patches  were  removed  from  the  
petri  dishes and kept  in desiccators  until use. 
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8. EVALUATION OF TRAMADOL HYDROCHLORIDE BUCCAL 
PATCHES 
 
The Tramadol hydrochloride Buccal Patches were evaluated for the following 
properties: 
8.1.  Physical parameters 
 Physical appearance and surface texture 
 Weight Uniformity 
 Thickness uniformity  
 Folding Endurance 
 Swelling Index.  
 Surface pH 
 
8.2. Mechanical parameters 
 
 In vitro residence time 
 In vitro drug release 
 content uniformity 
 Ex vivo permeation studies 
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8.1. Physical parameters:                      ( Padmaja Chimmiri .,et al.,2012) 
 
 a) Physical appearance and surface texture of patch: 
 
This parameter was checked simply with visual inspection of patches and 
evaluation of texture by feel or touch. 
b) Weight Uniformity of patches: 
 
Three patches of the size 29 mm diameters were weighed individually using 
digital balance and the average weights were calculated. 
 
 c) Thickness of patches: 
 
Thickness of the patches was measured using screw gauge with a least 
count of 0.01mm at different spots of the patches. The thickness was measured at 
three different spots of the patches and average was taken. 
 
d) Folding Endurance of patches: 
 
The flexibility of patches can be measured quantitatively in terms of what 
is known as folding endurance. Folding endurance of the patches was determined 
by repeatedly folding a small strip of the patches (approximately 2x2 cm) at the 
same place till it broke. The number of times patches could be folded at the same 
place, without breaking gives the value of folding endurance. 
 
e) Swelling Index of patches: 
The swelling Index of the patches determined by immersing pre weighed 
patch of size 29mm   in 50 ml water. The strip were taken out carefully at 5 and 
10 min. intervals, blotted with filter paper and weighed accurately. 
 
% Swelling Index = Wet Weight – Dry Weight ×100 Wet Weight 
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f) Surface pH of patches: 
 
                      Surface pH was determined by the patches were allowed in contact 
with 1ml of distilled water. The surface pH was noted by bringing a combined 
glass electrode or pH paper near the surface of patches and allowing to equilibrate 
for 1 min. 
8.2. Mechanical parameters 
8.2.1In vitro residence time 
The in vitro residence time  was  determined employing a  modified USP 
disintegration apparatus. The disintegration medium was composed of 800 ml 
isotonic phosphate buffer of pH 6.8 (IPB) maintained at  37±  0.50C.  A  piece  of  
porcine  buccal  tissue,  3 cm  length  was used for this study. The tissue was 
attached to a rectangular glass piece using cyanoacrylate adhesive from non-mucosal 
surface. The mucoadhesive patch was hydrated from one surface using pH 6.8 IPB 
and then the hydrated surface was brought  into contact with the  mucosal 
membrane. The glass slab was vertically fixed to the apparatus and allowed to move 
up and down so that the patch was completely immersed in the buffer solution at the  
lowest point and was out at the highest point.  The time necessary for complete 
erosion or detachment of the patch from the mucosal surface was observed and 
recorded (n=3).  
8.2.2 In vitro release study                              (Raghvendra Rao NG., et al.,2011.) 
The in vitro drug release studies were performed by using USP dissolution 
test apparatus (paddle method) .A film of 29mm diameter size was cut and 
attached to a glass slide with a few drops of phosphate buffer (pH 6.8). This slide 
was kept at an angle of 45º in a 1000 ml beaker containing 250 ml of phosphate 
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buffer pH 6.8 solutions. The dissolution medium was maintained at a temperature of 
37 ± 0.5º C and stirred at 50 rpm. At predetermined time intervals samples were 
withdrawn and replaced with fresh dissolution medium. The samples were filtered 
through 0.45μm Whatman filter paper and made appropriate dilutions with 
phosphate buffer pH (6.8). Absorbance was measured using UV- VISIBLE 
spectrophotometer. Drug release and the cumulative percentage of drug released 
were determined 
Table 8.1: Parameters were used for the dissolution study 
Apparatus USP Dissolution  apparatus (Type I) 
Dissolution medium Phosphate buffer (pH 6.8) 
Temperature 37 +  0.5 °C 
Volume 250 ml 
Speed 50 rpm 
Sample withdrawn 5 ml 
Running Time 7hrs  
 
8.2.3 Content Uniformity                                      ( Padmaja Chimmiri .,et al.,2012)         
Content uniformity was determined by dissolving one patch of   29mm 
diameter contain 5 mg of Tramadol Hydrochloride in  10  ml  of  phosphate  buffer  
solution (pH6.8). And the contents were stirred with the help of magnetic stirrer to 
dissolve the film. The contents of solution were transferred to a volumetric flask (10 
ml). The absorbance of the solution was measured against the corresponding blank 
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solution at 271 nm using UV spectrophotometer. The experiments were carried out 
in triplicate for each formulation and average value was calculated. 
 
8.2.4 Ex vivo permeat ion  studies  
  Sheep buccal mucosa was used as a barrier membrane. The buccal mucosa of 
freshly sacrificed sheep was procured from the local slaughter house. The buccal 
mucosa washed in isotonic phosphate buffer of pH 6.8 and used immediately.  The 
permeability across the sheep buccal   membrane was determined in order to evaluate 
diffusion studies by using Franz diffusion cell. 
         The buccal mucosa was mounted between the donor and receptor compartments.  
The receptor compartment was filled with 25 ml of isotonic phosphate buffer of 
pH6.8 which was maintained at 37 ± 0.2º C and stirred with a magnetic bead at 50 
rpm. At regular intervals of time samples were withdrawn and diluted appropriately 
and absorbance was analyzed using an UV-VIS spectrophotometer at 271 nm. 
 
 
8.2.5 Kinetics of In-vitro drug release 
In-vitro drug released data was subjected to in- vitro kinetic models such 
as zero order, first order, Higuchi and Korsemeyer- Peppas. 
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 Zero order: 
 
C = K0t 
 
Where    K0 - is the zero-order rate constant expressed in units of 
concentration/time 
 
t -is the time in hrs. 
 
First order: 
Log C = LogC0 – Kt / 2.303 
 
Where C0 - is the initial concentration of drug, 
 
 K - is the first order constant 
 
 t - is the time in hrs. 
 
 
Higuchi:    
Qt = Kt1/2 
 
Where    Qt - is the amount of the release drug in time t, 
 
 K- is the kinetic constant and t- is time in hrs 
 
 
KorsmeyerPeppas: 
Mt/ M∞ = Kt n 
 
Where  Mt - represents amount of the released drug at time t, 
 
 M∞- is the overall amount of the drug (whole dose) released after 12 hrs 
 
 K- is the diffusional characteristic of drug/ polymer system constant 
 
 n- is a diffusional exponent that characterizes the mechanism of release  
 of drug. 
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Table 8.2: Diffusion exponent and solute release mechanism 
 
 
Diffusion exponent (n) 
 
Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
 
 
 
8.2.6 STABILITY STUDIES                       (Manavalan R. and Ramasamy S., 2004) 
In any rational drug design or evaluation of dosage forms, the stability 
of the active component was a major criterion in determining their acceptance or 
rejection. 
 
Objective of the study 
The purpose of stability testing was to provide the evidence on how the 
quality of a drug substance or drug product varies with time under the influence of a 
variety of environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. The International 
Conference on Harmonization (ICH) Guidelines titled “Stability testing of New 
Drug Substances and Products describes the stability test requirements for drug 
registration application in the European Union, Japan and the States of America. 
ICH specifies the length of study and storage conditions 
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Long-Term Testing:  
Room temperature; 25° C ±2° C at 60% RH ±5% for12 months 
Accelerated Testing:  
Accelerated temperature ;40°±2° C at 75%RH ±5% for 6 Months In present 
study the optimized formulation F9 was exposured   up to 3 months stability studies 
at accelerated condition (40° C ±2° C at 75% RH ±5%RH) to find out the effect of 
aging on drug content and In-vitro drug release. 
 
Procedure 
 
The formulation (F7) was stored at accelerated condition in aluminum foils 
for 3 months. The samples were withdrawn after end of 1st month, 2nd month and 
3rd month. The samples were analyzed for its drug content and in vitro drug 
release. 
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9. RESULTS AND DISCUSSION  
 
 
9.1. PREFORMULATION PARAMETERS 
 
9.1.1. Identification of drug by FTIR spectroscopy 
 
The  FTIR  spectrum   of  Tramadol hydrochloride  was  shown  in  
Figure  9 . 1  and  the interpretations of IR frequencies were represented in         
Table 9.1. 
 
Figure 9.1: FTIR spectrum of Tramadol hydrochloride 
 
 
Interpretation of FTIR Spectrum 
Major functional groups present in Tramadol HCl show characteristic peaks 
in FTIR  spectrum.  The  major  peaks  are  identical  to  functional  group  of 
Tramadol HCl  Hence, the sample was confirmed as Tramadol HCl. 
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Table 9.1: Characteristic frequencies in FTIR spectrum of Tramadol HCl 
 
 
Inference Wave no.(cm-1) 
N-H stretching,O-H stretching 3636-3307 
C-H stretching(in-plane) 3065-2860 
C=C stretching 2668-1578 
C-H bending 1461-1383 
C-O Stretching 1289-1053 
C-N Stretching 1194-1289 
C-H bending(out-plane) 837-982 
 
b) Melting point 
 
Melting point values of Tramadol HCl sample was found to be in range of 
180º C to 184º C .The reported melting point for Tramadol HCl was 181±1.150 C. 
Hence, experimental values were same as official values.  
 
9.1.2. Physicochemical parameters of drug 
 
 
 Organoleptic properties: 
 
Physical state: Fine powder 
 
Colour            : A white fine powder 
 
Odour             :   Characteristic 
 
Taste              :   Bitter to alkaline 
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 Solubility study 
 
 
Table: 9.2 Solubility of Tramadol HCl in various solvents 
 
 
Name of solvent 
Standard Parts of 
solvent required for 
part of solute 
Solubility 
Distilled water From 1 to 10 Freely Soluble 
Methanol From 10 to 30 Soluble 
Isopropyl alcohol From 100 to 1000 Slightly soluble 
pH 6.8 From 10 to 30 Soluble 
pH 7.4 From 10 to 30 Soluble 
Glacial acetic acid More than 10000 Partially insoluble 
Acetone More than 10000 Partially insoluble 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucoadhesive Buccal Patches of Tramadol HCl Results and Discussion 
 
Adhiparasakthi College of Pharmacy, Melmarvathur.                                      Page 79 
 
 
9.2Analytical methods 
 
 DETERMINATION OF λ MAX OF TRAMADOL HCl BY USING DISTILLED 
WATER BY UV SPECTROPHOTOMETRY: 
The absorption maximum for Tramadol hydrochloride was found at 271.5nm 
 
 
 
 
Figure 9.2: λ max observed for Tramadol HCl  in distilled water. 
 
 
 Preparation of standard graph of Tramadol hydrochloride 
UV absorption spectrum of Tramadol hydrochloride in distilled water 
showed λ max at 271.5 nm was shown in figure 9.2 Absorbance obtained for 
various concentrations of Tramadol hydrochloride in distilled water were 
represented   in Table 9.3.  The graph of absorbance vs. concentration for Tramadol 
hydrochloride was found to be linear in the concentration range of 5–25 μg/ml. 
The drug obeys Beer- Lambert’s law in the range of 5–25 μg /ml was shown in 
figure 9.3. 
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Table 9.3: Data of concentration and absorbance for 
Tramadol HCl in distilled water 
  
 
 
S.No. 
 
 Concentration 
 
(µg/ml) 
 
 
Absorbance 
1 0 0.000 
2 5 0.180 
3 10 0.361 
4 15 0.552 
5 20 0.772 
6 25 0.940 
 
 
 
    
Figure 9.3:  Standard curve for Tramadol hydrochloride in distilled water 
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Table 9.4 Data for calibration curve parameters for distilled water 
 
 
S. No. 
 
Parameters 
 
Values 
 
1 
 
Correlation coefficient (r) 
 
0.9995 
 
2 
 
Slope 
 
0.026 
 
3 
 
Intercept 
 
0.2420 
 
 
 
 
 DETERMINATION OF λ MAX OF TRAMADOL HCl BY USING pH6.8 BY 
UV SPECTROPHOTOMETRY: 
 
The absorption maximum for Tramadol hydrochloride was found at 271.5nm 
 
 
 
 
 
 
Figure 9.4: λ max observed for Tramadol HCl in pH 6.8(phosphate buffer). 
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Preparation of standard graph of Tramadol hydrochloride 
 
UV absorption spectrum of Tramadol hydrochloride in pH 6.8(phosphate 
buffer) showed λ max at 271.5 nm was shown in figure 9.4. Absorbance obtained for 
various concentrations of Tramadol hydrochloride   in pH 6.8 were represented   in  
Table  9.5.  The graph of absorbance vs. concentration for Tramadol hydrochloride 
was found to be linear in the concentration range of 5–25 μg/ml. The drug obeys 
Beer- Lambert’s law in the range of 5–25 μ/ml was shown in figure 9.5. 
     Table 9.5:Data of concentration and absorbance for Tramadol HCl in pH6.8 
 
  
 
 
S.No. 
 
 Concentration 
 
(µg/ml) 
 
 
Absorbance 
1 0 0.000 
2 5 0.150 
3 10 0.303 
4 15 0.454 
5 20 0.602 
6 25 0.754 
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Figure 9.5: Standard curve for Tramadol hydrochloride in pH 6.8     
Table 9.6 Data for calibration curve parameters in pH 6.8. 
 
 
S. No. 
 
Parameters 
 
Values 
 
1 
 
Correlation coefficient (r) 
 
0.9998 
 
2 
 
Slope 
 
0.032 
 
3 
 
Intercept 
 
0.0261 
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 DETERMINATION OF λ MAX OF TRAMADOL HCl BY USING  pH 7.4 BY 
UV SPECTROPHOTOMETRY : 
 
The absorption maximum for Tramadol hydrochloride was found at 
271.5nm 
 
 
 
 
 
Figure 9.6: λ max observed for Tramadol HCl in pH 7.4(phosphate buffer). 
 
Preparation of standard graph of Tramadol hydrochloride 
 
UV absorption spectrum of Tramadol hydrochloride in pH 7.4(phosphate 
buffer) showed λ max at 271.5 nm was shown in figure 9.6.  Absorbance obtained 
for various concentrations of Tramadol hydrochloride   in pH 7.4 were represented 
in T a b l e 9 . 7 .  The graph of absorbance vs. concentration for Tramadol 
hydrochloride was found to be linear in the concentration range of 5–25 μg/ml. 
The drug obeys Beer- Lambert’s law in the range of 5–25 μg/ml was shown in 
figure 9.7. 
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Table 9.7: Data of concentration and absorbance for Tramadol HCl in pH 7.4 
  
 
 
S.No. 
 
 Concentration 
 
(µg/ml) 
 
 
Absorbance 
1 0 0.000 
2 5 0.162 
3 10 0.324 
4 15 0.487 
5 20 0.672 
6 25 0.811 
 
 
 
 
 
 
 
 
Figure 9.7: Standard curve for Tramadol hydrochloride in pH 7.4 
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Table 9.8 Data for calibration curve parameters in pH7.4 
 
 
S. No. 
 
Parameters 
 
Values 
 
1 
 
Correlation coefficient (r) 
 
0.9996 
 
2 
 
Slope 
 
0.0613 
 
3 
 
Intercept 
 
0.0477 
 
 
 Percentage purity of drug 
 
The  percentage  purity  of  drug  was  calculated  by  using  calibration  
graph method (least square method). 
Table: 9.9 Data of percentage purity of drug 
 
 
 
S. No. 
 
Percentage purity (%) 
 
Avg. percentage 
purity (%) 
 
1 
 
99.87 
 
 
 
 
 
100.11±0.240 
 
2 
 
100.12 
 
3 
 
100.35 
 
                           *All values are expressed as mean± S.D., n=3 
The percentage purity for Tramadol Hcl in BP 2009 is not less than 99.0 % 
and not more than 101.0 % of the stated amount of Tramadol HCl.  
 
 Determination of compatibility for drug with polymer by FTIR spectroscopy 
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Figure 9.8 FTIR spectra of  Tramadol HCl 
 
 
 
 
        Figure 9.9 FTIR spectra of Tramadol HCl  with  sodium alginate 
 
 
 
 
       Figure 9.10 FTIR spectra of Tramadol HCl with HPMC 
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               Figure 9.11 FTIR spectra of Tramadol HCl with carbopol 934 
 
 
 
 
 
Figure 9.12 FTIR spectra of Tramadol HCl with NaCMC 
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Table 9.10 The major peak observed in FTIR spectrum of Tramadol HCl and 
Tramadol HCl with different polymers used in formulations. 
 
Wave 
No. 
(cm-1) 
 
Functional 
group 
Peak observed (Yes/No) 
 
Tramadol HCl 
Tramadol HCl + 
 
Sodiumalginate 
Tramadol HCl + 
 
HPMC 
Tramadol HCl + 
 
carbopol 934 
Tramadol 
HCl + 
 
NaCMC 
3636-3307 N-H,O-H 
Stretching 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
3065-2860 
 C-H 
Stretching 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
2668-1578 C=C 
stretching 
 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
1461-1383 C-H bending 
(in-plane) 
 
 
Yes 
 
 
Yes 
 
 
Yes 
 
 
Yes 
 
 
Yes 
1289-1053 C-O Stretching  
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
1194-1289  
C-N Stretching 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
837-982 
C-H bending 
(out-plane) 
 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
The   major   peaks   of Tramadol hydrochloride spectrum   were   compared   to 
Tramadol hydrochloride with polymers spectrum. There was no interaction between 
Tramadol Hydrochloride and polymers .The peaks were represented in table 9.10 and 
spectrums where shown in figure 9.8 to 9.12.  
 
 DSC thermal analysis:  
The interactions between Tramadol hydrochloride and polymers were 
determined by DSC studies and results were represented in Table 9.11 and 
Thermogram curves where shown in Figure 9.13 to 9.17. 
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Figure 9.13: DSC thermogram for Tramadol hydrochloride 
 
 
 
Figure 9.14: DSC thermogram for Tramadol hydrochloride  
with Sodium alginate 
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Figure 9.15: DSC thermogram for Tramadol hydrochloride with       
carbopol 934 
 
 
 
 
Figure 9.16: DSC thermogram for Tramadol hydrochloride with HPMC 
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Figure 9.17: DSC thermogram for Tramadol hydrochloride with NaCMC 
 
Table 9.11: Various DSC thermogram parameter 
 
 
 
 
 
S. No. 
 
 
 
 
DSC Graphs 
 
 
Peak 
 
( ºC ) 
 
Onset 
temperature 
( ºC ) 
 
Endset 
temperature 
( ºC ) 
1 Tramadol Hcl 182.19 167.63 190.01 
 
2  
 Tramadol Hcl + sodium 
alginate 
 
181.38 
 
170.30 
 
185.81 
 
3 
 
Tramadol Hcl + carbopol 
934 
 
180.83 
 
169.01 
 
186.93 
 
4 
 
Tramadol Hcl + HPMC 
 
180.70 
 
171.80 
 
184.38 
 
5 
 
Tramadol Hcl + NaCMC 
 
180.83 
 
169.01 
 
187.93 
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9.3 EVALUATION OF TRAMADOL HYDROCHLORIDE LOADED 
MUCOADHESIVE BUCCAL PATCHES 
 
Physical appearance and surface texture of patches: 
 
These parameters were checked simply with visual inspection of 
patches and by feel or touch. The observation reveals that the patches are 
having smooth surface and they are elegant in appearance. 
Weight uniformity of patches: 
 
The weight of the patches was determined using digital balance 
and the average weight of all patches was given in Table 9.12. 
 
The drug loaded patches (29 mm) were tested for  uniformity of 
weight. The patches were found uniform in weight. The average weight of 
formulation F1 , F2 and F3 composed of polymers such as sodium alginate 
and HPMC in various ratios   were weighed  about  34.66 ± 1.15 , 37.66 
±0.57  and  43.33 ±1.15 mg respectively. Formulation F4 and F5 
composed of polymers such as sodium alginate and carbapol 934 in various 
ratios were weighed  about  33.33 ±1.15 and 28.66 ±1.15 mg  respectively. 
Formulation F6 and F7 composed of polymers such as sodium alginate , 
HPMC and carbapol 934 in various ratios were weighed  about 25.00 ±1.73 
and 27.66 ±1.52 mg  respectively. Formulation F8 and F9 composed of 
polymers such as sodium alginate, HPMC and NaCMC in various ratios 
were weighed about 45.66 ±1.52 and 47.66±0.57 mg respectively. 
In all the cases the calculated standard deviation values were 
very low which they suggest that the prepared patches were uniform in 
weight. 
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Thickness of patches: 
 
The thickness of the patches was measured using screw gauge and the 
average thickness of all patches was given in Table 9.12. 
The drug loaded patches (29 mm) were tested for  thickness. . The average 
thickness of formulation F1, F2 and F3 composed of polymers such as sodium 
alginate and HPMC in various ratios   were about 0.55±0.05, 0.56±0.05 and 
0.52±0.05 mm respectively. The average thickness of formulation F4 and F5 
composed of polymers such as sodium alginate and carbapol 934 in various ratios 
were about 0.58±0.01 and 0.53 ±0.05 mm respectively. The average thickness of 
formulation F6 and F7 composed of polymers such as sodium alginate, HPMC 
and carbapol 934 in various ratios were   about 0.57±0.05 and 0.52±0.01 mm 
respectively. The average thickness of formulation F8 and F9 composed of 
polymers such as sodium alginate, HPMC and NaCMC in various ratios were   about 
0.54±0.05 and 0.58±0.05 mm respectively. 
In all the cases the calculated standard deviation values were very low 
which they suggest that the prepared patches were uniform in thickness 
 
 
Folding endurance of patches: 
 
The folding endurance gives the idea of flexible nature of patches. The 
folding endurance was measured manually, patches were folded repeatedly till it 
broke, and it was considered as the end point. The folding endurance was found 
optimum and the patches exhibited good physical and mechanical properties and 
the average folding endurance of all patches was given in Table 9.12. 
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The drug loaded patches (29 mm) were tested for  folding endurance. . The 
average folding endurance of formulation F1, F2 and F3 composed of polymers such 
as sodium alginate and HPMC in various ratios   were about 263.33±3.51, 
266.00±1.00 and 266.66±3.351 respectively. The average folding endurance of 
formulation F4 and F5 composed of polymers such as sodium alginate and 
carbapol 934 in various ratios were about 243.33±2.08 and 287.33±4.50 
respectively. The average folding endurance of formulation F6 and F7 
composed of polymers such as sodium alginate, HPMC and carbapol 934 in various 
ratios were   about 249.66±2.08 and 293.33±2.64 respectively. The average 
folding endurance of formulation F8 and F9 composed of polymers such as 
sodium alginate, HPMC and NaCMC in various ratios were   about 238±1.95 and 
276.66±2.0 respectively. 
 
Surface pH of patches: 
Surface pH was determined by bring the patches in contact with 1ml of 
distilled water. The surface pH was noted by bringing a combined glass electrode or 
pH paper near the surface of patches and allowing equilibrate for 1 min and the 
average surface pH of all patches was given in Table 9.12. 
The drug loaded patches (29 mm) were tested for  Surface pH. . The 
average Surface pH of formulation F1 , F2 and F3 composed of polymers such as 
sodium alginate and HPMC in various ratios   were  about  6.33±0.57 , 6.16±0.05 
and 5.76±0.05 respectively. The average Surface pH of formulation F4 and F5 
composed of polymers such as sodium alginate and carbapol 934 in various ratios 
were about 6.46±0.17 and 6.43±0.35 respectively. The average Surface pH of 
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formulation F6 and F7 composed of polymers such as sodium alginate, HPMC 
and carbapol 934 in various ratios were   about 5.8±0.37 and 6.4±0.26 respectively. 
The average Surface pH of formulation F8 and F9 composed of polymers such as 
sodium alginate, HPMC and NaCMC in various ratios were   about 5.76±0.15 and 
6.33±0.20 respectively. 
Considering the fact that acidic or alkaline pH may cause irritation to the 
buccal mucosa and influence the degree of hydration of polymer, the surface pH of  
the  buccal  patches  was  determined  to  optimize  both  drug  permeation  and 
mucoadhesion.  Attempts  were  made   to  keep  the  surface  pH  as  close  to 
buccal  /salivary  pH  as  possible,  by  the  proper  selection  of  the  polymer  for 
developing the buccal patches. The surface pH of all the patches was within the 
range of salivary pH.  No significant difference was found in surface pH of 
prepared patches. 
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Table-9.12: Physical evaluation of mucoadhesive buccal patches of Tramadol 
HCl 
 
*All values are expressed as mean± S.D., n=3  
 
 
Swelling index of patches: 
 
The swelling index of the patches was determined by immersing preweighed patch of 
size 10 mm in 50 ml water. The patches were taken out from petridish care fully at 
1,2,3,4,5,6 upto and 7 hr. intervals, blotted with filter paper and weighed accurately 
and the average swelling index of all patches was given in Table 9.13.  
 
• The evaluated patches showed high swelling index values 0f about 25.01% 
after 7hr in the case of formulation F7 due to the high swelling property of the 
polymer carbopol 934.  
 
Formulations 
 
 
Average Weight  
(mg) 
 
 
Average 
Thickness 
(mm) 
 
 
Average Folding 
Endurance 
 
     Surface pH 
 
F1 
 
34.66 ± 1.15 
 
0.55±0.05 
 
263.33±3.51 
 
6.33±0.05 
 
F2 
 
37.66 ±0.57 
 
0.56±0.05 
 
266 ±1.00 
 
6.16 ±0.05 
 
F3 
 
43.33 ±1.15 
 
0.52±0.05 
 
266.66±3.51 
 
5.76±0.11 
 
F4 
 
33.33 ±1.15 
 
0.58±0.01 
 
243 .33±2.08 
 
6.46 ±0.05 
 
F5 
 
28.66 ±1.15 
 
0.53 ±0.05 
 
287.33±4.50 
 
6.43±0.35 
 
F6 
 
25.000 ±1.73 
 
0.57±0.05 
 
249.66 ±2.08 
 
       5.8±0.37 
 
F7 
 
27.66 ±1.52 
 
0.52±0.01 
 
293.33±2.64 
 
6.4±0.26 
 
F8 
 
45.66 ±1.52 
 
0.54±0.05 
 
238 ±1.95 
 
5.76±0.15 
 
F9 
 
47.66±0.57 
 
0.58±0.05 
 
276.66±2.0 
 
       6.33±0.20 
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Table:9.13 :Data for swelling percentage studies 
 
FORMULATIONS 
SWELLING %  WEIGHT INCREASES 
1st 
hr 
2nd 
hr 
3rd 
hr 
4th 
Hr 
5th 
Hr 
6th 
hr 
7th 
Hr 
F1  12.48  12.52  12.68  13.12  13.43  14.03  14.21  
F2  11.82  11.92  11.92  11.98  12.04  12.58  13.02  
F3  12.34  12.48  12.97  13.00  13.46  14.51  15.18  
F4  16.12  16.41  16.48  16.80  16.81  16.95  17.01  
F5  15.01  15.15  15.60  15.64  15.90  16.00  16.12  
F6  17.3  17.48  17.80  17.90  18.15  18.30  18.41  
F7  21.4  22.10  22.60  23.50  23.90  24.75  25.01  
F8  14.82  14.90  15.00  15.45  15.80  15.85  15.91  
F9  13.96  14.00  14.08  13.14  13.00  12.90  12.50  
 
 
 
 
 
 
 
 
Figure 9.18 Comparative Swelling index of formulation F1 to F9 
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 Drug content uniformity of patches: 
Tramadol HCl   buccal   patches   prepared   with   various   polymers   were 
subjected to the evaluation for uniform dispersion of drug throughout the patch. In 
each case three patches were used and the average drug content was calculated, the 
results were represented in Table-9.14. The drug was dispersed in the range of 90.14 
± 0.07 to 98.75 ± 0.80 %. Suggesting that drug was uniformly dispersed throughout 
all prepared patches.The standard deviation value calculated for such formulation is 
very less which suggest that the results are reproducible and accuracy in the method 
used to prepare the patches. 
 
In-vitro residence time of patches 
The in vitro residence time was determined by employing a modified USP 
disintegration apparatus. The average In-vitro residence time of all patches was given 
in Table 9.14. 
The in vitro residence time of formulation F1, F2 and F3 composed of 
polymers such as sodium alginate and HPMC in various ratios were about 
3.43±0.12, 3.16±0.12 and 3.49±0.09 hrs respectively. The in vitro residence time of 
formulation F4 and F5 composed of polymers such as sodium alginate and 
carbapol 934 in various ratios were about 4.24±0.13 and 4.11±0.05 hrs respectively. 
The in vitro residence time of formulation F6 and F7 composed of polymers such 
as sodium alginate, HPMC and carbapol 934 in various ratios were   about 6.47±0.15 
and 7.15±0.13 hrs respectively. The in vitro residence time of formulation F8 
and F9 composed of polymers such as sodium alginate, HPMC and NaCMC in 
various ratios were   about 5.24±0.11 and 5.34±0.12 hrs respectively. 
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In vitro residence time for various patches prepared was in the range of 
3.16±0.12 to 7.15±0.13 hr depending on the mucoadhesion properties of the polymer 
used. This increased residence time that was mainly due to the strong mucoadhesive 
property of the Carbopol. 
 
 
Table-9.14 Data of in vitro residence time and drug content uniformity 
 
 
Formulations 
 
 
In Vitro Residence time 
(Hrs) 
 
Drug Content 
Uniformity 
% 
 
F1 
 
3.43±0.12 
 
93.38± 0.27 
 
F2 
 
3.16±0.12 
 
90.14 ± 0.07 
 
F3 
 
3.49±0.09 
 
92.36 ± 0.11 
 
F4 
 
4.24±0.13 
 
94.01± 0.40 
 
F5 
 
4.11±0.05 
 
91.27 ± 0.49 
 
F6 
 
6.47±0.15 
 
96.79± 0.07 
 
F7 
 
7.15±0.13 
 
98.75 ± 0.80 
 
F8 
 
5.24±0.11 
 
92.95 ± 0.11 
 
F9 
 
5.34±0.12 
 
96. 88± 0.81 
 
*All values are expressed as mean± S.D., n=3  
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Table-9.15: Datas of Ex-vivo permeation release studies of Tramadol HCl loaded 
mucoadhesive buccal patches 
 
 
 
Time 
in       
hrs 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 17.68±1.12 15.06±0.57 16.20±0.72 16.20±0.82 18.01±0.18 18.50±1.12 20.30±1.82 18.01±0.87 18.50±1.02 
1 22.05±0.15 21.18±1.62 21.93±0.16 21.93±0.10 24.70±0.67 26.87±0.10 25.70±0.10 23.55±1.12 24.90±0.57 
1.5 28.78±0.60 27.37±1.10 28.83±0.10 27.85±0.17 30.99±0.34 32.68±0.19 34.36±0.12 31.06±0.02 29.07±0.62 
2 36.26±1.72 34.59±0.52 34.51±1.52 35.91±0.82 38.13±0.12 40.26±1.62 41.58±1.10 38.05±0.92 36.54±1.12 
3 42.36±1.10 40.26±0.10 39.99±0.40 41.83±1.12 42.87±1.12 43.50±0.92 48.52±0.19 43.12±0.12 41.50±1.72 
4 48.91±0.19 45.53±1.18 46.86±1.32 46.06±0.10 47.62±1.22 49.32±0.10 59.24±0.49 48.88±0.87 46.97±0.56 
5 59.05±0.13 56.92±1.12 57.03±1.12 56.48±0.85 58.10±0.14 61.32±0.12 65.32±0.95 55.69±1.10 54.31±1.19 
6 64.99±1.12 63.58±1.02 63.51±1.19 62.74±1.02 66.40±0.18 68.18±0.14 70.92±1.92 62.32±1.02 61.02±0.92 
7 66.10±0.60 65.50±0.17 64.88±1.15 64.23±1.02 68.12±0.45 71.64±0.92 75.21±0.42 68.71±1.42 66.53±0.12 
 
 
*All values are expressed as mean± S.D., n=3  
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                                 Figure-9.19 Diffusion profile of formulation F1 
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                                   Figure-9.20 Diffusion profile of formulation F2 
 
 
 
                             Figure-9.21 Diffusion profile of formulation F3 
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                                  Figure-9.22 Diffusion profile of formulation F4 
 
 
 
 
 
 
                         Figure-9.23 Diffusion profile of formulation F5 
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                            Figure-9.24 Diffusion profile of formulation F6 
 
 
 
 
                      Figure-9.25 Diffusion profile of formulation F7 
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                     Figure-9.26 Diffusion profile of formulation F8 
 
 
 
 
 
 
 
                    Figure-9.27 Diffusion profile of formulation F9 
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              Figure-9.28 Comprehensive diffusion profile of formulation F1-F9 
 
 
 
 
 
 
The   Ex-vivo permeation from buccal patches varied with respect to the polymer 
composition and nature. An  increase  in drug  release  from  the  buccal patches was 
found with increasing  concentration of polymers  that were more  hydrophilic   in  
nature.  Among   all formulations, the formulation F7 was shown maximum Ex-vivo 
permeation (75.21 ± 0.42%) over a period of 7 hrs were observed .All the data of 
diffusion profiles were represented in table 9.15 and shown graphically in figure 9.19 
to 9.28. 
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Table 9.16 Data of in vitro release profile of Tramadol HCl loaded 
mucoadhesive buccal patches 
 
Time 
in       
hrs 
                                                                                       Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 22.18±1.12 24.84±1.34 22.18±0.49 22.81±1.52 23.75±0.94 26.71±1.82 25.15±1.12 21.71±0.18 23.43±0.56 
1 27.34±0.12 30.46±1.12 29.18±0.15 28.90±0.62 30.93±0.67 34.68±1.12 36.71±1.22 29.37±0.19 28.9±1.12 
1.5 35.15±0.42 37.34±0.82 34.06±1.02 37.18±0.42 38.59±1.32 41.71±0.52 44.53±1.22 37.65±0.60 35.93±1.22 
2 42.03±0.32 43.59±0.12 40.78±0.54 43.28±1.72 44.37±1.42 49.84±0.90 50.78±0.42 44.53±1.52 42.3±0.14 
3 53.43±1.12 55.15±1.12 49.78±0.70 51.56±1.12 53.43±1.10 56.71±1.14 57.96±0.62 53.25±0.56 49.53±0.22 
4 61.71±1.42 63.28±1.18 57.96±0.50 64.37±0.10 66.09±0.70 68.43±0.82 69.53±0.70 60.46±0.19 58.12±1.32 
5 67.34±0.52 67.18±0.68 64.84±1.14 67.34±0.68 68.75±0.92 73.59±0.72 74.21±1.12 70.62±0.16 65.15±1.42 
6 72.34±0.92 69.37±0.50 68.15±1.18 70.15±0.82 71.87±0.14 75.46±0.23 78.43±0.42 75.93±0.72 72.03±0.98 
7 74.27±1.16 71.71±1.14 70.78±1.02 71.10±1.52 73.43±0.13 77.50±1.22 82.03±0.82 78.28±1.22 75.78±0.18 
*All values are expressed as mean± S.D., n=3  
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Figure-9.29 In-vitro release profile of formulation F1 
 
                       Figure-9.30 In-vitro release profile of formulation F2 
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                             Figure-9.31 In-vitro release profile of formulation F3 
 
                                Figure-9.32 In-vitro release profile of formulation F4 
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                        Figure-9.33 In-vitro release profile of formulation F5 
 
Figure-9.34 In-vitro release profile of formulation F6 
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                              Figure-9.35 In-vitro release profile of formulation F7 
 
 
                          Figure-9.36 In-vitro release profile of formulation F8 
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                              Figure-9.37 In-vitro release profile of formulation F9 
 
           Figure-9.38 comprehensive In-vitro release profile of    formulations F1-F9 
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The data of in- vitro drug release profile from buccal patches varied with 
respect to the polymer composition and nature. An  increase  in drug  release  from  
the  buccal patches was found with increasing  concentration of polymers  that were 
more  hydrophilic   in  nature.  Among   all formulations, the formulation F7 was 
shown maximum in-vitro drug released (82.03 ±0.82 %)  over a period of 7 hrs was 
observed .All the in-vitro drug release profiles were represented in table 9.16  and 
showed in figure 9.29 to 9.38. 
 
 
9.4.12 Kinetics of Drug release 
The kinetics of In-vitro drug release was determined by applying the drug 
released data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer- Peppas. The results obtained were represented in Table 9.17 and shown 
in Figure 9.39 to 9.47. 
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Table 9.17:  In vitro drug released kinetics studies of all formulations 
 
 
 
Formulations 
Zero 
orde
r R2 
First 
order 
R2 
 
 
 
Higuchi 
 
R2 
Korresmayer 
Peppas 
 
Best fit 
model 
 
 
R2 
 
 
n 
F1 0.992 0.752 0.947 0.995 
 
0.4539 Peppas 
F2 0.990 0.766 0.928 0.993 
 
0.4437 Peppas 
F3 0.994 0.752 0.925 0.995 
 
0.4002 Peppas 
F4 0.989 0.832 0.958 0.993 
 
0.4771 Peppas 
F5 0.992 0.894 0.951 0.995 
 
0.4226 Peppas 
F6 0.993 0.872 0.928 0.994 
 
0.4588 Peppas 
F7 0.993 0.872 0.928 0.999 
 
0.3744 Peppas 
F8 0.988 0.841 0.909 0.991 
 
0.3481 Peppas 
F9 0.997 0.939 0.930 0.998 0.3475 Peppas 
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Figure 9.39: The best fit model of formulation F1 
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                                      Figure 9.40: The best fit model of formulation F2 
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Figure 9.41: The best fit model of formulation F3 
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Figure 9.42: The best fit model of formulation F4 
 
 
 
 
Figure 9.43: The best fit model of formulation F5 
 
 
 
 
 Figure 9.44: The best fit model of formulation F6 
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Figure 9.45: The best fit model of formulation F7 
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Figure 9.46: The best fit model of formulation F8 
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Figure 9.47: The best fit model of formulation F9 
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The drug released from the mucoadhesive buccal patches was diffusion 
controlled.   
 
9.4. STABILITY STUDIES 
 
The formulation F7 was further subjected to stability study at specified 
period in appropriate storage condition as per ICH guidelines .The formulation 
was monitored for appearance, surface pH, drug content, In-Vitro residence time,  
In-Vitro drug released and Ex-Vivo peremeation and  results  were  represented  in 
Table  9.18 and shown in figure 9.48.  
 
Table-9.18 Data of stability studies of formulation F7 
STABILITY 
STUDIES  
APPEARANCE  SURFACE 
PH  
CONTENT 
UNIFORMITY  
(%)  
IN-VITRO 
RESIDENCE 
TIME (HR)  
IN-VITRO 
DRUG 
RELEASE  
Ex-VIVO 
PEREMEA 
–TION     
 
Initial 
Smooth 
surface& elegant 
texture 
 
6.40±0.26 
 
98.75±0.80 
 
7.15±0.13 
 
82.03±0.82  
 
75.21 ±0.42  
 
First month 
Smooth 
surface& elegant 
texture 
 
6.29±0.09 
 
98.22±0.20 
 
7.05±0.05 
 
81.86±0.07  
 
75.03 ±0.05  
 
Second month 
Smooth 
surface& elegant 
texture 
 
6.20±0.01 
 
98.18±0.03 
 
6.45±0.05 
 
81.52±0.08  
 
74.52±0.12  
 
Third month 
Smooth 
surface& elegant 
texture 
 
6.09±0.03 
 
98.05±0.04 
 
6.27±0.02 
 
80.33±0.06  
 
74.09 ±0.73  
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                               Figure 9.48: Graphical representation of stability data 
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10. SUMMARY AND CONCLUSION  
 
• The main goal of the present  investigation efforts was to develop  and 
evaluate  new buccal patches comprising  a drug- containing mucoadhesive 
polymeric layer using polymers  like sodium  alginate,  sodium carboxy 
methyl cellouse,  Hydroxy propyl methyl cellouse,  and  Carbopol 934  in 
various combinations and proportions  and a drug-free  PVA-aluminum foil  
backing  membrane . 
• The  prepared  patches  were  evaluated  for  number  of  parameters  like 
physical  appearance, surface texture, weight uniformity, thickness of patches, 
folding endurance, surface pH, swelling index,  in vitro residence time, drug 
excipient interaction studies, drug uniformity ,Ex vivo drug permeation and in 
vitro drug release.  
• The patches prepared were checked visually for its appearance & surface 
texture. All the prepared patches were of smooth surface & elegant texture.  
• All the prepared patches using different concentration of various polymers 
were weighing in between 25 ±1.73 to 47.66 ±0.57 mg.  
• The patches showed folding endurance values in between 238.0 ±1.95 to 
293.33 ±2.64.  
• The evaluated patches showed high swelling index values 0f about 25.01% 
after 7hr in the case of formulation F7 due to the high swelling property of the 
polymer carbopol 934. Similarly surface pH of all the patches prepared was 
ranging in between 5.76±0.11 & 6.46±0.05pH. 
•  In vitro residence time for various  patches prepared  was in the range  of  
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3.16±0.12 to 7.15±0.13 hr depending on the mucoadhesion properties of the 
polymer used. This increased residence time that was mainly due to the strong 
mucoadhesive property of the Carbopol. 
•  The Fourier transform Infra-Red (FTIR) and Differential scanning 
calorimetry (DSC) studies indicate that Tramadol hydrochloride showed 
complete entrapment   within the polymer carrier bonding is suggested and 
there were no chemical interaction. 
• Similarly, the patches were also estimated to drug content uniformity study 
and it lies in between 90.14± 0.07 & 98.75 ± 0.80 % which suggest that 
uniform dispersion throughout the buccal patches. 
• The in- vitro drug release and Ex-vivo permeation from buccal patches varied 
with respect to the polymer composition and nature. An  increase  in drug  
release  from  the  buccal patches was found with increasing  concentration of 
polymers  that were more  hydrophilic   in  nature.  The formulation F7 was 
shown best one among the formulations (F1 to F9) were prepared. 
Formulation F7 in-vitro drug released was 82.03 ±0.82 % and Ex-vivo 
permeation was 75.21 ± 0.42% over a period of 7 hrs was observed.  
• The data of in-vitro release where fit in kinetic models . The kinetic models 
used were zero order equation, first-order equation, higuchi release and peppas 
model. The best fit with highest correlation coefficient (r) was shown by 
korsmeyer and Peppas (r=0.999). “n” value of all the formulation was less 
than 0.5,it shows that  the formulation F7 was follows Fickian model of drug 
release. 
• Form the stability data it can be concluded there was no significant change in 
appearance, surface pH, content uniformity, in-vitro residence time and in-
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vitro drug release, Ex-vivo peremeation release. Hence the formulation F7 was 
stable formulation. 
• The overall studies concluded that the formulation F7 was composed of 
Tramadol HCl(50mg), sodium alginate (700 mg ), HPMC (100 mg) and 
carbopol 934 (200 mg) showed satisfactory and better release profile. Hence 
the formulation F7 selected as best formulation. 
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11. FUTURE PROSPECTS  
 
 
In this present work, physio-chemical characterization and in vitro 
evaluation of Taramdol HCl loaded mucoadhesive buccal patches were performed. 
 In future in-vivo studies will be conducted to set in-vitro in-vivo correlation 
which is necessary for the successful formulation development. 
In future the long term stability studies are required to know the shelf life of 
the prepared buccal patches. 
The various formulations will be developed with Taramdol HCl using other 
polymer and plasticizers in future. 
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